





STEM CELLS ARE HIGHLY ENRICHED SOURCES OF 








A dissertation submitted to Johns Hopkins University in conformity with the 









© 2014 Tricia Cottrell 










Myositis, scleroderma, and other systemic autoimmune diseases are united by 
many features, including (i) the presence of a self amplifying cycle of tissue destruction 
and immune system activation with a failure of homeostatic tissue repair; (ii) an 
increased risk of cancer; and (iii) a strong association of particular clinical phenotypes 
with disease specific autoantibodies, which are used clinically for diagnosis and 
prognosis of disease.  Interestingly, most autoantigens identified to date are ubiquitously 
expressed proteins, despite their associations with highly specific patterns of tissue 
damage. Finally, there is a significant subset of patients with characteristic features of 
systemic autoimmunity that lack any known autoantibodies.  While most autoantigen 
identification studies to date have used tractable, immortalized cancer cell lines, we 
proposed that these cell types likely express only a small subset of proteins targeted in 
systemic autoimmune disease and the use of appropriately perturbed antigen sources that 
mimic changes in the target tissues are key to the discovery of novel autoantigens.   
Studies in autoimmune myositis focused on key characteristics of skeletal muscle 
in this disease, including the presence of a type I interferon signature and increased 
antigen expression by regenerating muscle cells, to identify two novel autoantigens, 
IFIT3 and MYL4.  These studies demonstrated a systematic triangulation approach to 
improve the efficiency of autoantigen identification, featuring: (i) antigen sources 
expressing pathways shown to be active in the diseased tissue in vivo; (ii) confirmation of 
spot selection by post-pluck immunoblotting prior to LC/MS/MS peptide sequencing; and 
(iii) the use of data from additional methods to filter the proteomic data, prior to rigorous 
experimental confirmation of antigen identity. 
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This approach was then applied to the study of scleroderma.  Based on the disease 
model that an antitumor immune response may be misdirected against progenitor cells 
involved in tissue repair, we sought to prove that differentiating progenitor cells are a 
target of the immune response in scleroderma.  Our studies demonstrate that the 
expression of known scleroderma autoantigens is altered during stem cell differentiation.  
Moreover, immunoblot screening of lysates from undifferentiated and differentiating 
stem cells with scleroderma patient sera revealed that roughly one third of randomly 
selected patients and 60% of ANA negative patients have autoantibodies targeting 
progenitor antigens, which are not expressed in HeLa cells and not targeted by 
autoantibodies in healthy controls.  Finally, two of these novel autoantigens were 
identified as keratin 8 and fetuin A. 
These studies outline a systematic approach to autoantigen identification that 
accommodates the complexity of protein dynamics in perturbed cells and limits the 
investment of time and financial resources necessary for the identification of any 
particular target.  These are the first studies to implicate differentiating progenitor cells as 
a target of the autoimmune response in scleroderma.  Finally, this work demonstrates the 
importance of screening antigen sources that approximate changes in the target tissue in 
order to identify novel autoantigens that have potential clinical utility as well as the 
possibility of providing mechanistic insights into these potentially devastating and poorly 
understood diseases. 
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Chapter 1:  General Introduction 
 
Systemic autoimmune diseases 
Human autoimmune diseases occur frequently (affecting in aggregate more than 
5% of the population worldwide), and impose a significant burden of morbidity and 
mortality on the human population (1).  Autoimmune diseases are defined as diseases in 
which immune responses to specific self-antigens contribute to the ongoing tissue 
damage.  Both the specificity of the immune response and its role in tissue damage are 
central components of the definition.  Unlike tissue-specific autoimmune diseases, where 
unique tissue-specific antigens are targeted, systemic autoimmunity is characterized by 
multiple affected tissues and adaptive immune responses to a variety of apparently 
ubiquitously expressed autoantigens (2). 
Although the definition appears relatively simple in concept, the complexity of 
this spectrum of disorders is enormous, and has greatly challenged elucidation of simple 
shared mechanisms. This complexity affects almost every domain, including genetics, 
phenotypic expression, and kinetics.  In the latter case, there is frequently a prolonged 
period (weeks to months) between initial onset of symptoms and development of the 
diagnostic phenotype, and disease may vary in expression in the same individual over 
time. 
In spite of this enormous complexity, there is a striking association of the clinical 
phenotype with the targets of the autoimmune response.  This association is, in fact, so 
strong that autoantibodies have been used for diagnosis and prognosis in the human 
autoimmune diseases (2).  For example, autoantibodies to the Sm splicing 
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ribonucleoprotein complex are diagnostic of systemic lupus erythematosus (SLE), and 
autoantibodies recognizing topoisomerase 1 are found in patients with the diffuse form of 
scleroderma.  While not thought to be directly pathogenic in most cases, the presence of 
high titer, class-switched autoantibodies requires suprathreshold concentrations of 
molecular epitopes not previously tolerized and encountered in a pro-immune context.  
Thus, the association of specific autoantibodies with distinct clinical phenotypes provides 
critical clues to understanding the mechanisms underlying the initiation and propagation 
of autoimmune diseases.  
 
Distinct phases in the development of autoimmunity: initiation and propagation 
By studying the development of autoantibodies over time in patients who 
subsequently manifest an autoimmune disease, significant data have demonstrated that 
the onset of an autoimmune response and the development of clinical symptoms are 
generally separated in time.  For example, rheumatoid arthritis (RA)-specific 
autoantibodies recognizing citrullinated proteins frequently precede the development of 
RA (3).  A landmark study in SLE expanded our understanding of this phenomenon.  
Harley and colleagues analyzed sera collected from patients in the US military who 
subsequently developed SLE (4).  Strikingly, patient autoantibodies could be divided into 
two groups: (i) those which precede the diagnosis of SLE by several years – these 
included antinuclear and antiphospholipid antibodies; and (ii) those which occurred 
around the time of onset of symptoms – these included anti-Sm, anti-RNP and to a lesser 
extent anti-DNA.  The observation that one group of autoantibodies precedes symptoms 
in SLE, and that another group appears coincident with the phenotype strongly suggests 
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that the groups mark distinct events in the development of autoimmune disease.  
Members of the first group are likely markers of disease initiation; members of the 
second group likely markers of disease propagation. The antigens targeted by the immune 
system in this latter phase (i.e. associated with clinical disease) are more likely to 
themselves have some function in disease-propagation, possibly through their possession 
of pro-inflammatory or adjuvant functions (5).  
 
Initiation phase: protein dynamics and determinants of antigen selection  
Initiation of an adaptive immune response requires presentation to T cells of 
suprathreshold concentrations of molecules with structure not previously tolerized by the 
host.  One of the more persuasive models proposed to explain the persistence of 
potentially autoreactive T cells within the repertoire of the host is that of 
immunodominance of T cell epitopes (6, 7).  Studies by Sercarz and colleagues(7) have 
stressed that while antigens contain numerous potential determinants that could be 
presented on major histocompatibility complex (MHC) class II during antigen 
processing, not all determinants in a particular molecule are equally likely to be 
efficiently presented.  Those determinants that are most efficiently presented are termed 
‘dominant’; those that are not loaded onto MHC class II to a significant degree are 
termed ‘cryptic’.  For self-antigens, it is likely that a constant set of dominant 
determinants are generated during antigen processing under most circumstances, with 
similar outcomes in the thymus and periphery.  Antigens processed by the ‘standard’ 
pathway are therefore fully tolerized, with the T cell repertoire purged of reactivity to the 
dominant self.  However, the balance of dominant and cryptic epitopes presented during 
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antigen processing is influenced significantly by changes of protein structure, which 
occur during various relevant physiological states (8).  Currently, there is evidence that 
post-translational modifications, proteolytic cleavage, and genetic changes altering 
protein structure are mechanisms that may alter antigen processing to reveal potentially 
cryptic epitopes in the initiation of systemic autoimmunity. 
 
Post-translational modification of autoantigen structure 
Autoantigens undergo a variety of post-translational modifications, including 
phosphorylation, proteolytic cleavage, ubiquitination, transglutamination, citrullination, 
and isoaspartyl modification (9).  In several cases, autoantibodies recognize exclusively 
the modified form of the antigen (e.g. RNA polymerase-II large subunit, SR proteins, 
citrullinated vimentin and other RA autoantigens), indicating that the modified forms of 
the molecules are important in driving the immune response.  In addition, Doyle and 
Mamula (9) have demonstrated that post-translational modification of autoantigen 
structure may be more broadly relevant than can be appreciated by studying autoantibody 
specificity alone.  They showed that whereas mouse immunization with a murine 
cytochrome c peptide (amino acids 90-104) resulted in no T or B cell response, 
immunization with the isoaspartyl form of this peptide resulted in strong T and B cell 
responses.  Although the autoantibodies elicited recognized both the modified and the 
native form of the antigen, the T cells only recognized the isoaspartyl form.  Similar 
observations have also been made for several SLE autoantigens (10).  The difficulty 
detecting and quantifying antigen-specific T cells in various autoimmune diseases may 




Novel antigen cleavage during cell damage, cell death, or inflammation 
Recent studies have provided evidence that single proteolytic events early in 
antigen processing may play critical roles in defining the epitopes generated.  For 
example, Watts and colleagues (reviewed in reference (11)) have conclusively 
demonstrated that early cleavage by asparagine endopeptidase (AEP) determines 
subsequent proteolytic events.  Modifications of the antigen that affect this early cleavage 
dramatically change the epitopes loaded onto MHC class II (11). 
Inflammatory microenvironments can create significant potential to load distinct 
epitopes because unique proteolytic activities are present.  Activated inflammatory cells 
constitute a major source of proteases, including various cytotoxic lymphocyte granule 
proteases (granzymes), as well as numerous neutrophil and monocyte granule proteases.  
It is of interest that numerous autoantigens targeted in systemic autoimmune diseases are 
substrates for these inflammatory proteases, and that unique autoantigen fragments are 
generated through the activity of granzyme B and potentially other similar proteases (11).  
Such autoantigen forms are not generated during other forms of cell damage or death, and 
similar activity is not observed against non-autoantigens.   Thus, novel proteolytic 
cleavage of intracellular autoantigens during activity of cytotoxic immune effector 
pathways may provide a source of cryptic epitopes not generated during homeostatic 
‘tolerance-inducing’ tissue turnover.  
 
Autoantigen alteration due to mutation, truncation, or splicing 
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Since the final epitopes generated and loaded onto MHC class II can be 
profoundly influenced by single, early cleavage events during antigen processing, 
relatively minor but critically placed changes in the primary structure of autoantigens 
may have the capacity to influence peptide selection. A study of the melanoma and 
vitiligo-associated autoantigens, tyrosinase-related proteins (TRP) 1 and 2, has strikingly 
demonstrated that this mechanism may play an important role in generating immune 
responses to self and tumor antigens (12).  In this study, Houghton and colleagues 
generated cDNA libraries encoding large numbers of random mutations in syngeneic 
TRP proteins and used a DNA immunization approach into black mice to test the 
immunogenicity of the altered proteins encoded by the pools of mutated cDNAs.  
Immunization with non-mutated proteins induced no detectable immune responses, but 
the mutated cDNA pools elicited both autoimmune depigmentation and the ability to 
reject melanoma tumors.  Additional analysis showed that autoimmunity resulted from 
mutations that altered autoantigen cell biology, particularly degradation rates and 
pathways.  Mutations also created new helper T cell epitopes, and induced recognition of 
non-mutated but previously cryptic epitopes.  Interestingly, mutations themselves did not 
form part of CD8 epitopes that drive the anti-self and anti-tumor immune responses.  
Mutated molecules that were immunogenic were frequently truncated, leading the authors 
to propose that inappropriately truncated self-proteins may provoke autoimmunity when 
present in a pro-inflammatory environment.  
 
Propagation phase: chronic inflammation driven by target tissue antigen expression 
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The striking association of specific autoantibody responses with distinct 
phenotypes suggests that autoantigen expression or form in specific target tissues may 
play an important role in both focusing the immune response and generating tissue 
damage. Recent studies on human autoimmune myopathies have begun to provide 
important insights into this problem. Myositis-specific autoantigens are expressed at very 
low levels in control muscle, but at high levels in myositis tissue, where antigen 
expression is at highest levels in regenerating muscle cells.(13) Interestingly, histidyl 
tRNA synthetase (HRS) expression is also found at high levels in lung and anti-HRS 
antibodies are associated with autoimmune myopathies with interstitial lung disease (14).  
Recently, 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) was identified 
as an autoantigen in patients with statin-associated autoimmune myopathy (15).  In 
addition to the induction of HMGCR protein expression by statin treatment of cultured 
cells, this group also demonstrated increased expression of this protein in regenerating 
muscle fibers of anti-HMGCR positive patients.  These data suggest that enhanced 
autoantigen expression in the target tissue may be a feature of disease propagation, and 
that antigen expression during tissue repair may provide an ongoing antigen source to 
sustain and amplify tissue damage.  
 
Systemic autoimmunity and cancer 
There are significant data linking autoimmunity and cancer. For example, cancer 
is present in ~20% of individuals with dermatomyositis, with a striking temporal 
clustering of cancer diagnosis around the time of diagnosis of the myositis (16, 17).  
Similarly, there is evidence for an association of SLE with cancer, particularly 
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lymphoma, again clustered within the first two years of SLE diagnosis (18, 19).  
Sjögren’s syndrome is also strongly associated with cancer—the relative risk for 
lymphoma in Sjögren’s patients is roughly 40 times that of the general population (20).  
Rheumatoid arthritis patients develop lymphoma at double the rate seen in the general 
population, a risk correlated with disease severity (21), but not the use of biological 
therapies (22).  Finally, a comprehensive review of the literature confirms an increased 
risk of malignancy in scleroderma.  In this disease, lung cancer is the most common 
malignancy, but the diagnoses of breast cancer and scleroderma show significant 
temporal association (23, 24).  These associations, both with timing of diagnosis as well 
as preferentially with specific tumor types, are strongly indicative of a non-random 
clustering of autoimmune processes and cancer, which is likely of mechanistic 
significance. 
There is also growing evidence that, when associated with ‘paraneoplastic’ 
autoimmune syndromes, cancers are frequently smaller at diagnosis and may have a 
better prognosis (25).  Perhaps the most striking evidence for a potential mechanistic 
association between autoimmunity and effective anti-cancer immunity comes from 
studies showing that development of autoimmunity during immunotherapy for a variety 
of different cancers is a predictor of a better cancer outcome.  This may target both (i) 
tissue-specific antigens (e.g. in metastatic melanoma, where development of vitiligo is a 
predictor of an effective anti-tumor response) (26)  or (ii) non-tissue-specific autoantigens 
(e.g. systemic high dose adjuvant interferon α-2b therapy for metastatic melanoma 
inducing new autoantibodies) (27).  These associations suggest that autoimmunity can be 




A model of mechanism in systemic autoimmunity 
A mechanistic explanation for the association between systemic autoimmunity 
and cancer has been elegantly explored using autoantibodies specific for myositis, a 
disease in which skeletal muscle is known to be the target of the autoimmune response.   
From work done in the Rosen lab, three intriguing observations have led to a compelling 
model of disease:  first, regenerating muscle fibers in myositis patients express high 
levels of autoantigens whereas the levels are much lower in fully differentiated, healthy 
muscle; second, antigen expression correlates with myoblast differentiation status in 
vitro; and finally, cancers associated with myositis also express high levels of these 
autoantigens whereas the corresponding healthy tissues do not (13).  These data suggest 
that in myositis, an anti-cancer immune response may be misdirected at muscle 
progenitor cells, resulting in immune mediated injury of regenerating muscle tissue.   
Myositis, scleroderma, and other systemic autoimmune diseases are united by 
many features, including their associations with autoantibodies and cancer, as well as the 
presence of a self amplifying cycle of tissue destruction and immune system activation 
with a failure of homeostatic tissue repair.  These diseases are also united by the fact that 
most autoantigens identified to date are ubiquitously expressed proteins, which is 
incongruent with the highly specific patterns of tissue damage observed in these diseases. 
Finally, there is a significant subset of patients with characteristic features of systemic 
autoimmunity that lack any known autoantibodies.  These commonalities support the 
conclusion that undiscovered autoantibodies likely exist and that in addition to their 
potential clinical utility, identification of the targets of these autoantibodies may lend 
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significant insights into the underlying mechanisms driving the initiation and propagation 
of these devastating diseases. 
 
Thesis overview 
Despite the identification of numerous disease specific autoantibody specificities, 
many of which tightly correlate with clinical phenotype and prognosis, the role of these 
targeted proteins in the initiation and propagation of systemic autoimmunity remains 
largely elusive.  Although some studies have shed insight on a possible role for target 
tissue progenitor cells as drivers of the immune response through high levels of 
autoantigen expression, these studies have been limited to myositis, in which the target 
tissue is well defined and amenable to sampling.  In contrast, scleroderma is a disease in 
which the precise target of the immune response is unknown and a potential role for 
tissue progenitors in driving the immune response has not been explored.   
While most autoantigen identification studies to date have used tractable, 
immortalized cancer cell lines, these cell types likely express only a small subset of 
proteins targeted in systemic autoimmune disease.  In contrast to previous studies, we 
propose that the use of appropriately perturbed antigen sources that mimic changes in the 
target tissue(s) are key to the discovery of novel autoantigens not detected using 
conventional antigen sources (Figure 1).  Moreover, using cells that more closely mimic 
the true targets of the immune response will likely provide insight into underlying disease 
mechanisms. 
In order to streamline the identification of novel autoantigens, it was necessary to 
develop a systematic approach to antigen identification that accommodates the 
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complexity of protein dynamics in perturbed cells while simultaneously limiting the 
investment of time and financial resources necessary for the identification of any 
particular target.  In order to develop such a system, we initially focused on studies in 
autoimmune myositis (with known target tissue and stronger understanding of disease 
mechanism) to develop methods to identify novel antigens from disease relevant antigen 
sources.   
We next sought to apply those methods to the study of scleroderma, a disease in 
which the target of the immune response is unknown.  Based on the disease model that an 
antitumor immune response may be misdirected against progenitor cells involved in 
tissue repair, we sought to prove that differentiating progenitor cells are a target of the 
immune response in scleroderma.  The identification of progenitor specific autoantigens 
in scleroderma may provide important mechanistic understanding and enable the 
development of disease specific therapies that are desperately needed in this potentially 












Figure 1:  Venn diagram illustrating the importance of protein sources in antigen 
identification.  Previous experiments seeking to identify the targets of autoantibodies 
have used cell lines such as HeLa (cervical cancer derived) or Hep2 (laryngeal carcinoma 
derived) cells as antigen source(s), which are tractable, readily available and may differ 
tremendously from the cell type(s) targeted by the immune response.  Currently known 
autoantigens likely only reflect the small subset of proteins targeted that are expressed in 
both commonly used cell lines and the true target cell type(s).  In contrast, using an 
appropriately perturbed antigen source (such as a differentiating tissue progenitor) that 
approximates the cell type(s) targeted by the immune response (pink) will allow the 








High titer autoantibodies are frequently observed in systemic autoimmunity, 
where they are often associated with specific phenotypic manifestations (28, 29).  These 
antibody specificities are therefore useful for diagnosis and prognosis, and provide 
insights into disease mechanisms.  Paradoxically, the vast majority of antigen targets 
identified to date in systemic autoimmunity are ubiquitously expressed, a finding that is 
difficult to reconcile with the highly specific patterns of tissue damage observed in these 
diseases.  For example, antibodies against aminoacyl tRNA synthetases are found only in 
patients with myositis (in which muscle and lung are the primary target organs), and yet 
these proteins perform an essential function in all cells. Similarly, topoisomerase 1 and 
centromere proteins are necessarily present in all cell types and are well defined 
autoantibody targets in systemic sclerosis, a disease in which the skin, lungs, and 
gastrointestinal tract are most commonly affected.  In addition, many patients with 
systemic autoimmune diseases lack known autoantibody specificities (e.g., in myositis, 
~20-40% of patients are autoantibody negative as assessed using currently available 
clinical assays (30)).   
In several autoimmune diseases, autoantibodies recognize post-translationally 
modified proteins, such as citrullinated proteins in rheumatoid arthritis (10, 11) and 
proteins susceptible to granzyme B cleavage (31).  It has been proposed that perturbations 
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that result in the modification or enhanced expression of particular proteins may drive the 
immune response in some autoimmune diseases.   
In the inflammatory myopathies, an increasing body of data supports a role for 
disease-specific changes in antigen expression within the target tissue in driving the 
disease-specific immune response.  For example, expression of Mi-2 is increased 
specifically in dermatomyositis (DM) muscle, the disease in which Mi-2 autoantibodies 
are found (13).  Additionally, Mi-2 is expressed at high levels in regenerating muscle 
cells, but only at low levels in differentiated muscle cells (32). Similarly, 3-hydroxy-3-
methylglutaryl-coenzyme A reductase expression is dramatically upregulated by statins 
both in cultured cells, as well as in muscle from patients with statin-induced necrotizing 
myopathy (of note, these patients make high titer autoantibodies to this enzyme) (15).  
Antibodies targeting melanoma differentiation-associated protein 5 (MDA5) have also 
recently been identified in myositis patients previously considered antibody negative (33, 
34).  Interestingly, expression of this protein is highly induced by interferon-α (IFN-α), a 
finding consistent with the strong type I IFN signature that has been well documented in 
the muscle of patients with DM (35).   
The data suggest that screening the appropriately perturbed antigen source, which 
mimics changes identified in the target tissue in that disease, may enable the discovery of 
novel autoantibodies.  We have therefore focused on autoantibody discovery using 
antigen sources in which pathways known to be active in the target tissue in situ are 
recapitulated; examples described here are exposure to type I IFN and muscle 
regeneration.  Whereas several methods of antigen identification exist, including 
screening of recombinant cDNA expression libraries (SEREX), peptide libraries, and 
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multiple affinity protein profiling, few accommodate the complexity of protein dynamics 
observed in vivo, such as splice variants, post-translational modifications, cleavage, 
nucleic acid binding, inducible expression, and cryptic epitope exposure.   
Serological proteome analysis (SERPA), which combines two-dimensional (2D) 
electrophoresis with immunoblotting and tandem mass spectrometry (36), is currently one 
of the most useful techniques to define modified autoantigens.  A major advantage of this 
method is the high sensitivity of both immunoblotting and tandem mass spectrometry, 
allowing the detection of relatively low abundance antigens within a complex protein 
mixture (37).  This approach is, however, significantly limited by the fact that selection of 
a low abundance protein spot on a 2D gel by alignment with a patient serum immunoblot 
is often insufficiently precise.  Since numerous candidate proteins are generated by 
tandem mass spectrometry (MS/MS) sequencing (38), it is critical that candidate antigens 
are rigorously confirmed to eliminate false positives.  This confirmation often requires a 
substantial investment of time and resources before the correct protein is confirmed. 
This chapter describes a rapid multidimensional method of autoantigen discovery 
using patient sera as probes.  Using a combination of (i) cells subjected to a perturbation 
known to be present in the diseased tissue; (ii) a modified SERPA strategy that confirms 
that the relevant spot has been plucked from the gel before sequencing; and (iii) mRNA 
expression profile data that define molecules whose expression is enhanced by the 
perturbation, enables rapid autoantigen identification. Data is shown that details the 
identification process for two novel autoantigens whose expression is regulated in the 




Materials and methods 
 
Human sera 
Frozen aliquots of de-identified sera from 141 myositis patients, obtained during 
routine blood draws at the Johns Hopkins Myositis Center, were used in the preliminary 
screens for this study. Patients were clinically defined according to the Bohan and Peter 
criteria (39, 40). Normal sera from 50 healthy donors were also used.  All samples were 
obtained, and studies were performed, in compliance with Institutional Review Board and 
Health Insurance Portability and Accountability Act regulations. 
 
Cell culture 
Human salivary gland (HSG) cells were a generous gift from Dr. Bruce Baum and 
were cultured in minimal essential medium (MEM; Invitrogen) with 10% heat-
inactivated fetal calf serum (HI FCS), 1% L-glutamine, and 1% penicillin/streptomycin at 
37°C with 5% CO2.  Human cervical epithelial cells (HeLa) were cultured in Dulbecco’s 
modified eagle medium (DMEM; Invitrogen) low glucose with 10% HI FCS, 1% L-
glutamine, and 1% penicillin/streptomycin at 37°C with 7.5% CO2.  Second passage 
primary human keratinocytes (Lonza) were grown in Keratinocyte Basal Medium-2 
(KBM-2) supplemented with the KGM-2 bullet kit (Lonza) without subculturing.  For 
IFN treatment, cells were grown to 70% confluence before being cultured for an 
additional 24 hours in the absence or presence of 1000 units/mL IFN-α (Sigma).   Normal 
human skeletal muscle cells were cultured and induced to differentiate into myotubes 




Lysate preparation from cultured cells and human muscle biopsies 
Culture dishes were kept on ice during two washes with cold phosphate buffered 
saline (PBS) followed by scraping into lysis buffer (1% Nonidet P-40 (NP40); 20 mM 
Tris, pH 7.4; 150 mM NaCl; one mM ethylenediaminetetraacetic acid (EDTA)) 
containing a protease inhibitor cocktail.  Human muscle biopsies were obtained from 
patients seen at the Johns Hopkins Myositis Center.  Surgical procedures were performed 
for patient management, and the research tissue samples were in excess of that required 
for routine diagnostic purposes.  Collection and use of the human biopsy specimens were 
approved by the Johns Hopkins Institutional Review Board.  All patient samples were 
deidentified, with clinical and laboratory features linked only to the patient code.  
Detergent extracts were prepared in lysis buffer from frozen muscle biopsies obtained 
from DM and polymyositis (PM) patients, and from a control individual, as described 
(13).  Patients were defined as having DM or PM if they had probable or definite disease 
according to the Bohan and Peter criteria (39, 40).  All lysates were diluted to working 
concentrations in gel application buffer (2% SDS; 4% glycerol; 40 mM Tris-HCl, pH 6.8; 
0.002% bromophenol blue; 1% β-mercaptoethanol) and boiled for three minutes.   
 
Immunoblotting 
Primary immunoblotting screens using lysate pairs from HSG and HeLa cells 
incubated in the absence or presence of IFN-α or muscle cells at various stages of 
differentiation, were performed as follows.  Five μg/lane of each lysate was 
electrophoresed on seven cm, 10% SDS-PAGE gels for 170 Vh, then transferred to 
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nitrocellulose membranes at 100 V for one hour.   Membranes were stained with Ponceau 
(0.3% w/v in 3% trichloroacetic acid) and washed with distilled H2O to identify 
molecular weight markers, followed by blocking for one hour at room temperature (RT) 
in 3% bovine serum albumin in wash buffer (WB) (ten mM Tris-HCl, pH 7.6; 0.5% 
NP40; 150 mM NaCl).  Membranes were then incubated with patient serum diluted in 
WB (1:5000) for one hour at RT.  After extensive washing with WB  (five washes for 
five minutes each), membranes were subsequently incubated with a horseradish 
peroxidase-conjugated goat anti-human IgG secondary antibody (Jackson 
Immunoresearch) at 1:10,000 dilution in WB for one hour.  Membranes were then 
washed as above and incubated with enhanced chemiluminescent reagent (Pierce) 
followed by exposure to X-ray film.  For serum M4, a second screen including lysates 
from HSGs, HeLas, and primary human keratinocytes treated with 1000 units/mL IFN-α 
was performed as described above.  
 
2-Dimensional (2D) electrophoresis 
IFN-α treated cells and muscle cells at day four of differentiation were washed 
twice with cold PBS followed by two washes with cold 200 mM Sucrose, ten mM Tris 
HCl, pH 7.4 and lysed directly into isoelectric focusing (IEF) buffer (eight M urea, two 
M thiourea, 4% 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate 
(CHAPS), 1% dithiothreitol and protease inhibitors).  First dimension focusing was 
performed using Bio-Rad ReadyStrip immobilized pH gradient (IPG) Strips and Protean 
IEF Cell per manufacturer’s instructions.    Seven cm IEF strips were used to determine 
the optimum pH range for the protein of interest whereas 17 cm IEF strips were used for 
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sequencing.  Briefly, each seven cm IEF strip was loaded with 130 μl consisting of 100 
μg lysate, 1.5% 2-hydroxyethyl disulfide, 0.1% bromophenol blue and 0.4% ampholytes 
(pH dependent on IEF strip pH range).  For 17 cm strips, 300 μg lysate was used in a 
total volume of 300 μl.  Up to 12 IEF strips can be run simultaneously; these can 
subsequently be processed immediately for the second dimension gel (see below), or they 
can be stored at -80°C.  Prior to running the second dimension gels, IEF strips were 
incubated for 20 minutes at RT in ten mg/ml dithiothreitol, followed by 20 minutes in 25 
mg/ml iodoacetamide, both in equilibration buffer (six M urea; 0.375 M Tris-HCl, pH 
8.8; 2% SDS; 20% glycerol).  IEF strips were then loaded onto 10% SDS PAGE gels (16 
cm or seven cm gels, depending on the size of the IPG strips), covered with 1% low melt 
agarose (Promega) and electrophoresed as described above (16 cm gels were 
electrophoresed for 850 volt hours, and transferred onto nitrocellulose membranes for 
four hours at 400 mA).  To ensure consistency, IEF strips run in parallel were used for 
2D immunoblotting and corresponding protein sequencing experiments.   
 
2D immunoblotting and antigen localization 
2D gels were transferred to nitrocellulose membranes, stained with Ponceau to 
visualize resolved protein spots, and scanned at high resolution for alignment with the 
subsequent immunoblots.  Immunoblots were performed as described.  During X-ray film 
exposure, precise documentation of the membrane perimeter on the film is critical for 
subsequent alignment of the exposed film with a printout of the Ponceau scan.  This 
enables the immunoblotted spot of interest to be aligned with the corresponding Ponceau-
stained protein spot.  Once the protein of interest is located on the Ponceau scan, nearby 
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spot patterns can be used for orientation to find the same spot on the preparative gel for 
plucking and protein identification. 
 
Protein identification 
Preparative SDS-PAGE second dimension gels were made using solutions and 
procedures that minimize exposure to airborne contaminants.  All glassware and 
equipment were only used for proteomics experiments and were washed twice with 0.1% 
SDS (w/v) followed by extensive rinsing with ultrapure distilled water and 100% 
methanol to minimize protein contamination.  After performing first and second 
dimension gel runs as described, gels were fixed in destain (14% v/v acetic acid; 24% v/v 
methanol) for 15 minutes, incubated for one hour in Gel Code Blue Stain (Thermo 
Scientific) and then destained in ultrapure distilled water for two to four hours. Destained 
gels were placed on a light box to facilitate visualization of stained protein spots, and gel 
plugs containing the protein spot of interest and a nearby “blank” gel plug containing no 
visible protein were carefully removed from the preparative gel using a sterile pipette tip. 
The gel plugs were immediately washed twice in 50% methanol for ten minutes each 
with shaking and stored at -20°C.  The remaining preparative gel was washed three times 
for five minutes each in running buffer (25 mM Tris-HCl; 200 mM glycine; 0.1% (w/v) 
SDS), and proteins were transferred to nitrocellulose membrane for immunoblotting to 
verify successful plucking.  Gel plugs confirmed to contain the protein of interest were 
sent to the Johns Hopkins Mass Spectrometry and Proteomics Facility for liquid 





Total RNA was extracted using the Trizol reagent method (Invitrogen) from 
HSGs cultured for 24 hours in the absence or presence of IFN-α at [1000 units/ml], and 
from muscle cells at various stages of differentiation (days zero to five).  All samples 
were collected in triplicate.  Additional purification was performed on RNeasy columns 
(Qiagen), and the quality of total RNA samples was assessed using an Agilent 2100 
Bioanalyzer (Agilent Technologies). Biotin-labeled, complementary RNA (cRNA) was 
prepared from total RNA according to the chip manufacturer’s protocol (Illumina).  
cRNA was hybridized to Illumina HumanHT12 v3 Expression BeadChips, and signal 
was detected with streptavidin-Cy3 (IFN treatment).  cRNA was hybridized to Illumina 
Sentrix HumanRef-8 Expression BeadChips, and signal was detected with streptavidin-
Cy3 (muscle cell differentiation).  All signal intensity quantification was performed using 
an Illumina BeadStation 500GX Genetic Analysis Systems scanner.   
 
Analytical methods and statistical analysis for microarray data 
IFN treatment - A single intensity (expression) value for each Illumina probe on 
the array was obtained using Illumina BeadStudio software with standard settings and no 
background correction.  The expression values for all the probes for each sample were 
scaled to have median 256 (2
8
) and then log (base 2) transformed.  Genes (i.e., Illumina 
probes) considered to be differentially expressed between two groups of samples were 
those satisfying the following criteria:  (i) Welch t-test p-values less than or equal to 0.01 
(10
-2
) (41); (ii) a Benjamini-Hochberg false discovery rate (FDR) less than or equal to 
0.25 (42); (iii) a fold change above 2.0 (calculated using geometric means); and (iv) the 
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expression value of the gene is above the Illumina BeadStudio calculated background for 
all three samples in the group.  
Muscle cell differentiation - Preliminary analysis of the scanned data was 
performed using Illumina BeadStudio software.  Any gene consistently below a 
background threshold level of D=.98 for all samples was eliminated from further 
analysis.  Bead averaged data were normalized by Z transformation.  Briefly, microarray 
data were log10 transformed and data were standardized to the mean expression of the 
dataset and represented in terms of a  score.    
 
Antigen identity confirmation 
Embryonic myosin light chain 4 (MYL4) cDNA was cloned from myoblasts at 
day four of differentiation, and was sequence verified.  Interferon-induced protein with 
tetratricopeptide repeats 3 (IFIT3) cDNA (Origene) and MYL4 cDNA were transiently 
transfected into HeLa cells using Lipofectamine (Invitrogen), per the manufacturer’s 
protocol.   
Mouse monoclonal anti-IFIT3 and anti-MYL4 antibodies were obtained from BD 
Transduction Labs and Novus, respectively.  Cell lysates were transferred onto 
nitrocellulose membranes and blocked in Tris buffered saline/Tween 20 (TBST; ten mM 
Tris-HCl, pH 7.4; 150 mM NaCl; 0.05% (v/v) Tween 20) with 5% (w/v) powdered milk 
for one hour at RT.   Membranes were then incubated with anti-IFIT3 or anti-MYL4 
antibodies (diluted 1:3,000 or 1:1,000, respectively, in TBST/5% milk) overnight at 4°C.  
Membranes were washed five times for five minutes each with TBST/5% milk at RT, 
followed by incubation with a 1:10,000 dilution of horseradish peroxidase conjugated 
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anti-mouse secondary antibody in TBST/5% milk for one hour at RT.  After washing five 
times for five minutes each using TBST buffer, membranes were incubated for five 
minutes with enhanced chemiluminescent reagent (Pierce) and then exposed to X-ray 
film.   
35
S-methionine-labeled IFIT3 protein was synthesized using the TNT T7 Coupled 
Reticulocyte Lysate System (Promega) for in vitro transcription and translation (IVTT) 
using IFIT3 cDNA per the manufacturer’s instructions.  Immunoprecipitations using 
35
S-
methionine-labeled IFIT3 protein were performed as described, with all steps carried out 
at 4
o
C (33). Briefly, one μl of IVTT product was diluted in lysis buffer with protease 
inhibitors, one μl of patient serum was added and the mixture was rotated for one hour.  
35 μl of immobilized Protein A agarose (Pierce) was then added, and the mixture was 
rocked for 20 minutes.  Immunoprecipitates were subsequently washed four times with 






Detection of IFN-α induced autoantigens, and selection of a novel specificity 
To screen for new autoantibodies targeting IFN-α-induced proteins, lysates made 
from untreated and IFN-α treated cells were immunoblotted with myositis patient sera.  A 
representative screening blot performed on untreated and IFN- α treated HSGs is shown 
(Fig. 2A).  Several different patterns were observed:  some sera immunoblotted proteins 
present exclusively in IFN-α treated cell lysates (e.g., the 60 kDa protein blotted by M4); 
others blotted proteins present at baseline, but upregulated by IFN-α (e.g., the 52 kDa 
protein blotted by M1 and M3); some blotted proteins whose expression remained 
unchanged (e.g., M2 and M5) and some did not blot anything (e.g., M6).  We focused on 
sera that detected novel specificities induced by IFN-α treatment; hence, of the DM 
patient sera shown in Fig 2A, only M4 was of interest (the 52 kDa band blotted by M1 
and M3 is Ro52 (TRIM21), an autoantigen which is known to be targeted in patients with 
myositis).  Of note, we found antibodies recognizing IFN-α induced proteins in 16/141 
(11%) of the myositis sera; IFN-inducible specificities were never detected with healthy 
control sera (data not shown). 
A subsequent screen was performed to determine if the 60 kDa antigen blotted by 
serum M4 could be detected in other cell types treated with IFN-α.  As shown in Fig 2B, 
the 60 kDa protein was also detected in HeLa cells and primary human keratinocytes 
upon treatment with IFN-α, suggesting that local type I IFN signaling may induce 
autoantigen expression by a variety of cell types.  Moreover, this enabled the use of data 




Antigen identification strategy 
We next pursued the identification of the 60 kDa protein using 2D gel 
electrophoresis and LC/MS/MS peptide sequencing.  A critical aspect of this 
methodology is precise localization of the protein of interest by immunoblotting a 
replicate 2D gel (Fig. 3A).  It is important to scan the Ponceau stained membrane prior to 
immunoblotting because careful alignment of the immunoblot with a printout of the 
scanned Ponceau image allows identification of the antigenic protein spot to be plucked.  
The surrounding pattern of spots visible only on the Ponceau scan is critical for locating 
the spot of interest on an identically run preparative 2D gel stained with colloidal blue 
(Fig. 3B).  Of note, spot identification can be a challenging step if the antigen of interest 
is relatively low abundance (hence faintly stained, as highlighted for the M4 antigen in 
Fig. 3B), which may result in inaccurate plucking.  Once removed, the gel plug is sent for 
peptide sequencing by LC/MS/MS and a list of candidate proteins is generated by 
BLAST searching all of the peptide sequences generated against a mammalian protein 
sequence database (MASCOT).  Although only a tiny gel plug containing the spot of 
interest is used for sequencing, the high sensitivity of the LC/MS/MS frequently results in 
lists of ~10-20 candidate proteins from the detected peptides, even after subtracting 
contaminants sequenced from a nearby “blank” gel plug.  Pursuing candidate lists 
obtained from inaccurate spot selections therefore wastes significant time and resources 
to eliminate spurious candidates. 
We therefore developed a rapid, inexpensive quality control step to confirm that 
the correct protein spot is plucked before sequencing, and have confirmed that this 
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dramatically improves the efficiency and accuracy of antigen identification.  This is 
accomplished by transferring the proteins remaining after plucking to a nitrocellulose 
membrane, and immunoblotting with the patient serum.  If the spot of interest is 
accurately plucked, there will be a halo of signal around the removed spot (as is shown in 
the boxed area, Fig. 3C).  In those cases where it is challenging to accurately identify 
which spot to pluck, we recommend performing several plucks (including multiple gels 
and a variety of cell types when possible), and performing a post-pluck immunoblot on 
each. This strategy rapidly and inexpensively identifies the best gel plug, and only this is 
then sent for sequencing.  LC/MS/MS peptide sequencing of a confirmed pluck of the M4 
antigen from IFN-α treated HeLa lysate resulted in a list of twelve candidate proteins in 
the 50-75 kDa range that were absent from a nearby “blank” gel plug (Table 1).  As 
expected, most of these proteins also had a predicted isoelectric point (pI) similar to that 
observed for the antigen of interest (estimated to be ~5.2 from the 2D immunoblot).   
The triangulation approach requires at least one additional piece of information 
about the protein of interest to allow multiple different paths of pursuit to converge on the 
correct antigen identity.  Fortuitously, in the case of antigen M4, we were able to take 
advantage of expression profiling data from IFN-α treated cells performed for an 
unrelated project.  We compared the list generated by proteomic sequencing of the 
antigen from IFN-α treated HeLa lysate (Table 1) to a list of genes that were induced by 
at least two-fold in IFN-α treated HSGs (Table 2).  This analysis quickly enabled us to 
focus on a single leading candidate present on both lists: IFN-induced protein with 




Confirmation of antigen identity 
Several strategies were used to definitively demonstrate that the protein targeted 
by high titer serum autoantibodies of patient M4 is IFIT3.  (i) Immunoblots performed 
with a monoclonal anti-IFIT3 antibody confirmed that IFIT3 is strongly induced in IFN-α 
treated HeLa cells and that it comigrates with the 60 kDa M4 protein (Fig. 4A, lanes 1, 2, 
5 & 6); (ii) Both the M4 patient serum and the anti-IFIT3 monoclonal antibody 
immunoblot a 60 kDa protein expressed in HeLa cells transiently transfected with IFIT3 
cDNA (Fig. 4A, lanes 4 & 8), but absent in untransfected cells (lanes 3 & 7); and (iii) 
35
S-methionine labeled IFIT3 (
35
S-IFIT3) was generated by IVTT using IFIT3 cDNA.  
Serum M4 immunoprecipitated 
35
S-IFIT3 (Fig. 4B), whereas other myositis patient sera 
known to be anti-IFIT3 antibody negative (as assessed by immunoblot of IFN-α induced 
cell lysates, data not shown), did not.  Healthy control sera also did not 
immunoprecipitate 
35
S-methionine-IFIT3 (data not shown). 
 
Validation of the above approach using muscle cells at successive stages of 
differentiation to screen for new myositis autoantibodies: identification of MYL4 
We sought to validate the approach described above by using similar methods to 
detect myositis autoantigens whose expression is enhanced in the context of additional 
pathways active in diseased tissue.  Specifically, since myositis autoantigen expression 
has been demonstrated to be enhanced in differentiating muscle cells (13), we used these 
as a novel source for autoantigen discovery.  Myositis serum S293 immunoblotted a 28 
kDa band that was robustly expressed in muscle cells at day four (or thereafter) of 
differentiation, but was absent from myoblasts (day zero cultures), as well as HeLa, HSG 
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and keratinocyte lysates (Fig. 5A and data not shown).  Lysates made from myoblasts 





 dimension, 12% SDS-PAGE).  Duplicate runs were done:  the first gel was 
transferred to nitrocellulose and used for immunoblotting with serum S-293 to identify 
the spot corresponding to the 28 kDa protein.  The second, replicate gel was stained with 
colloidal coomassie blue immediately after SDS-PAGE, and the 28 kDa spot was plucked 
and processed for peptide sequencing, after confirming by post-pluck blotting that the 
correct spot had been plucked 
To aid in identifying the real target autoantigen from the resulting list of candidate 
proteins, we used microarrays to obtain gene expression patterns during myoblast 
differentiation (days zero to five).  In the case of the unidentified 28 kDa antigen, there 
were eight candidate proteins from the 2D proteomic analysis.  Two of the top candidates 
were known muscle-specific proteins; embryonic myosin light chain 4 (MYL4) and 
troponin I, skeletal slow twitch (TNNI).  When these were searched in our myoblast 
differentiation gene expression database, only one was absent at day zero, but was 
dramatically increased after three to four days of differentiation. This antigen was MYL4, 
a muscle-specific, differentiation stage-specific 28 kDa protein (Fig. 5B), making it the 
top candidate. 
We validated that serum S293 does have antibodies to MYL4 in the following 
ways. Immunoblots performed using a monoclonal anti-MYL4 antibody confirmed that 
the kinetics of expression during myoblast differentiation were identical to those seen 
using S293 serum (Fig. 5C).  Furthermore, the 28 kDa band blotted by both the 
monoclonal antibody and S293 co-migrated (Fig. 5D).   Lastly, we cloned the cDNA for 
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MYL4 from day four myoblast cultures and transiently transfected it into HeLa cells.  
The 28 kDa band was detected by immunoblotting in transfected lysates only, using both 
the monoclonal antibody and serum S-293 (Fig 5D).  Taken together, the above 
approaches confirm that the 28 kDa antigen blotted by S293 is MYL4.   
 
Expression of IFIT3 and MYL4 in muscle biopsy lysates 
We used lysates made from muscle biopsies (the target tissue in myositis) to 
examine expression of IFIT3 and MYL4 in vivo.  Lysates were made from control, DM 
and polymyositis (PM) muscle.  IFIT3 was detected in DM muscle only, and was absent 
from PM and control muscle (Fig. 6, lanes 4-6), consistent with the well-documented 
type 1 IFN signature in DM muscle (43).  Of note, IFIT3 expression was also found to be 
enhanced (though at lower levels) during muscle differentiation (absent at day zero, 
present at day four, Fig 6 lanes 1 & 3).  MYL4 was robustly expressed in both DM and 
PM muscle biopsy lysates but was not detected in control muscle (Fig. 6).  This 
expression pattern is consistent with immunohistochemical data showing extensive 











The triangulation approach described here has three main features that improve 
the efficiency of autoantigen identification (Fig. 7): (i) Use of antigen sources that 
express pathways shown to be active in the diseased tissue in vivo (e.g., specific cell or 
tissue types, differentiation stages, activated signaling pathways, etc).  This may allow 
the detection of novel autoantigens of mechanistic importance missed by other screening 
strategies; (ii) Confirmation of spot selection by post-pluck immunoblotting prior to 
LC/MS/MS peptide sequencing; and (iii) Use of data from additional methods (e.g. 
biochemical properties of the antigen, microarray analysis of gene expression) to filter 
the proteomic data, prior to rigorous experimental confirmation of antigen identity. This 
filtering step narrows the number of candidates and limits the expense and time required 
for confirmation.  As used in this study, an antibody specific for the protein candidate 
and/or a cDNA expression plasmid are very useful in providing unequivocal evidence of 
antigen identity.  Additional methods of antigen identity confirmation may include 
knocking down expression of the protein with specific siRNAs, screening a knockout cell 
line, comparison of protease specific cleavage patterns, or 2D immunoblotting to confirm 
exact co-localization using the patient serum and a protein specific antibody.   
A potential disadvantage of this strategy is that identification of proteins by 2D 
gel and LC/MS/MS sequencing can be challenging for very large and poorly soluble 
proteins (37), such as those in cell membranes, although sequencing of cleavage 
fragments instead of the full length protein may circumvent this limitation.  Post-
translational modifications also may pose significant challenge, as the modified residues 
can result in peptide fragments that are difficult to identify, especially in the case of 
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glycosylation (38). Furthermore, filtering by changes in gene expression is not suited to 
autoantigens generated by post-translational modification. Evaluating novel antigens for 
post-translational modifications prior to sequencing permits the identification of 
modifications that should be included in the analysis of the LC/MS/MS data and 
potentially allows for their removal prior to sequencing.  Finally, if a novel antigen is a 
protein that has not been previously identified, it may be absent from the mammalian 
database and thus may also be missed by this approach. 
These studies emphasize that current technologies enable rapid and efficient 
autoantigen discovery, and allow novel autoantigens expressed in pathways relevant to 
disease pathogenesis to be defined. Such autoantigen targets – when induced by immune 
effector or tissue repair pathways - may be of particular importance in amplifying and 
sustaining injury in these diseases. These molecules may provide a new class of probes 




Table 1:  Candidate proteins generated by LC/MS/MS peptide sequencing of a 2D 
gel spot containing the 60 kDa M4 antigen, listed in order of strength and restricted 
to those with a predicted MW of 50-75 kDa.   
 
         MW  Gene 
GI Number Protein
a





gi|31542947 60 kDa heat shock protein, mitochondrial   61.1 5.7 HSPD1 
gi|1777782 Interferon-induced protein with tetratricopeptide repeats 3 55.9 5.1 IFIT3 
gi|28317  Keratin 10      58.8 5.1 KRT10 
gi|20070228 Nucleobindin 1      53.9 5.1 NUCB1 
gi|35655  Protein Disulfide Isomerase    57.1 4.8 P4HB 
gi|624873 Rab GDI alpha      50.4 5.2 GDI1 
gi|547754 Cytokeratin-2e      65.9 8.1 KRT2 
gi|2343085 Programmed cell death protein 4    51.7 5.0 PDCD4 
gi|12803709 Keratin 14      51.7 5.1 KRT14 
gi|1136741 T complex protein 1 subunit theta    58.6 5.8 CCT8 
gi|2160719 Myc box-dependent-interacting protein 1   64.7 5.0 BIN1 
gi|121570 78 kDa glucose-regulated protein    72.3 5.1 HSPA5 
 
a
 Only proteins predicted to be 50-75 kDa are shown. 
b 
Predicted based on amino acid sequence.   
GI = GenInfo Identifier; aa = amino acids; MW = molecular weight; kDa = kilodaltons; 







Table 2:  Genes whose transcripts are induced by ≥2 fold with IFN-α treatment of 
human salivary gland (HSG) cells with predicted MW of 50-75 kDa. 
 
Gene Symbol       Fold Induction           Length (aa)           MW (kDa)
a
  
IFI44    28.2   444   50.5 
IFI44L    30.1   452   51.3 
BCL2L13   2.04   485   52.7 
WARS    3.45   471   53.2 
TRIM38   2.52   465   53.4 
TRIM21   5.97   475   54.2 
IRF7    13.73   503   54.3 
MUC13   2.56   511   54.5 
IFIT2    12.88   472   54.6 
SERPING1   2.2   500   55.2 
IFIT1    27   478   55.4 
IFIT5    2.43   482   55.8 
IFIT3    31.2   490   56.0 
LAP3    3.94   519   56.2 
TRIM5    3.46   493   56.3 
TRIM22   8.9   498   56.9 
TRIM69   2.9   500   57.4 
BTN3A1   2.09   513   57.7 
OASL    8.33   514   59.2 
EIF2AK2   3.34   551   62.1 
REC8    2.25   547   62.6  
SLC15A3   6.93   581   63.6 
BTN3A3   2.09   584   65.0 
LGALS3BP   4.04   585   65.3 
UNC93B1   2.33   597   66.6 
GBP1    4.16   592   67.9 
TRIM25   2.13   630   71.0   
 
a
 Predicted based on amino acid sequence.   





Figure 2:  Patient sera detect novel myositis autoantigens in IFN-α treated cells. (A) 
Immunoblot screen of untreated and IFN-α treated HSG cell lysates with six myositis 
patient sera (M1-M6). Note that patient M4 has high titer autoantibodies targeting a 60 
kDa protein only detectable after IFN-α treatment (lanes 7 & 8). Migration of molecular 
weight standards are shown down the left side. (B) IFN-α treatment induces expression of 
the 60 kDa M4 antigen in HSG, HeLa and primary keratinocyte cultures.  Vinculin blot 






Figure 3:  Immunoblot confirmation of protein spot selection increases antigen 
identification efficiency.  (A)  2D immunoblot of IFN-α treated lysate using patient 
serum M4.  First dimension: pI 3-10 IEF; second dimension, 10% SDS-PAGE.  The area 
outlined by the white box is magnified in the lower right corner of each image.  (B)  
Identical replicate preparative gel stained with gel code blue.  The spot to be plucked 
(marked with the arrow) is identified by aligning the Ponceau stained transfer and the 
immunoblot obtained in A.  (C)  Immunoblot confirming accurate removal of a gel plug 
containing the antigen of interest from the preparative gel.  Note the halo of signal visible 




Figure 4:  Confirmation that the 60 kDa M4 antigen is IFIT3.  (A) Immunoblots were 
performed with lysates made from HeLa cells incubated in the absence (lanes 1 & 5) or 
presence (lanes 2 & 6) of IFN-α, or transiently transfected with IFIT3 cDNA (lanes 4 & 
8) or vector only (lanes 3 & 7).  Equal amounts of protein were loaded in each gel lane.  
Immunoblots were performed with monoclonal anti-IFIT3 antibody (lanes 1-4) or M4 
serum (lanes 5-8).  (B) 
35
S-methionine labeled IFIT3 is immunoprecipitated by the M4 












Figure 5:  Confirmation that the 28 kDa antigen blotted by S293 serum is MYL4.  
(A & C)  Immunoblots were performed with lysates made from muscle cells harvested at 
various times during differentiation, using serum S293 (panel A) and monoclonal anti-
MYL4 antibody (panel C).  Equal amounts of lysate were electrophoresed in each gel 
lane.  (B)  Gene expression profiles of muscle cells harvested at days zero through five of 
differentiation show that MYL4 gene expression is absent at day zero, but is robust by 
day four, a pattern consistent with the protein expression in the same lysates.  TNNI gene 
expression remained low throughout differentiation.  Gene expression values are 
represented as a Z-score. (D)  Untransfected HeLa cell lysates (denoted “MYL4 -”), or 
HeLa cells transiently transfected with MYL4 cDNA (denoted “MYL4 +”, middle lane of 
each set), or muscle cells at day four of differentiation were immunoblotted with 
monoclonal anti-MYL4 antibody or S293 serum.  MYL4 (28 kDa) was detected in 
transfected HeLa cells and the day four muscle cell lysates by both.  Equal protein 
amounts were electrophoresed in all gel lanes.  (A, C & D)  Vertical lines between lanes 





Figure 6:  IFIT3 and MYL4 are detected in myositis muscle biopsy lysates, but not 
in control muscle.  Lysates made from undifferentiated myoblasts (day zero) incubated 
in the absence or presence of IFN-α (lanes 1 & 2),  muscle cells at day four of 
differentiation (lane 3) and lysed muscle biopsies from patients with PM, DM or control 
individuals (lanes 3-6) were immunoblotted with monoclonal antibodies against IFIT3 or 
















Figure 7:  Summary of the triangulation approach to antigen identification.  This 
strategy can be adapted for a variety of antigen identification investigations.  Efficient 
antigen identification is facilitated by focusing on a disease relevant antigen source, 
confirming accurate plucking of the protein spot of interest by immunoblotting the 
remaining 2D gel, and combining multiple pieces of information about the antigen to 








Scleroderma, also known as systemic sclerosis, is a heterogeneous systemic 
autoimmune disease characterized by immune activation, vasculopathy, and fibrosis.  
Biopsies of early diseased tissue show damage to small vessels, particularly arterioles, 
with signs of endothelial cell activation and apoptosis, smooth muscle cell and pericyte 
proliferation, and fibroblast activation (44).  Although this vasculopathy results in tissue 
hypoxia and the upregulation of numerous angiogenic factors, including vascular 
endothelial growth factor (VEGF), scleroderma patients exhibit severe impairments in 
their ability to repair and replace damaged vessels (45-47).  Ultimately, this pathology 
manifests as an array of clinical phenotypes that can include skin fibrosis, esophageal 
dysfunction, interstitial lung fibrosis, pulmonary arterial hypertension, and renal crisis 
(48).   
Although the mechanism of disease initiation and propagation remains a mystery, 
several lines of evidence suggest a prominent role for the immune system in scleroderma 
pathogenesis.  Patient biopsies show that early pathogenic changes in small blood vessels 
are accompanied by pronounced perivascular mononuclear immune cell infiltration 
consisting primarily of T and B cells, macrophages, and mast cells (49).  There are also 
reports of associations between particular HLA class II molecules and scleroderma 
clinical phenotypes (50, 51), increased serum levels of Th2 cell-derived cytokines (52), 
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and oligoclonal expansion of T cells in scleroderma skin lesions (53) – all suggesting that 
the immune response in scleroderma is antigen specific.   The strongest evidence 
implicating the immune system in scleroderma pathogenesis is the production of high 
titer, class-switched disease specific autoantibodies, which are used for diagnosis and 
prognosis of the disease (48).   
 
Autoantibodies in scleroderma 
Anti-nuclear autoantibodies (ANAs) are found in ~90% of scleroderma patients 
and specific antibodies are often associated with specific clinical phenotypes (49).  For 
example, anti-centromere antibodies (ACA) are associated with limited cutaneous 
scleroderma and an increased risk for calcinosis, digital loss, and pulmonary 
hypertension.  In contrast, anti-topoisomerase 1 antibodies (anti-topo 1) are very specific 
for patients with diffuse cutaneous scleroderma and pulmonary fibrosis.  A third example 
is the association of antibodies against RNA polymerase III with severe skin sclerosis and 
an increased risk of renal crisis (54). 
Although these antibodies are clinically useful, their role in the pathogenesis of 
scleroderma remains unclear.  For instance, antibody titers do not strictly correlate with 
disease severity and several autoantibodies have been identified in multiple different 
autoimmune diseases, suggesting that the antibodies themselves are unlikely to be 
pathogenic.  Target antigens identified to date are mostly intracellular, ubiquitously 
expressed proteins, which is incongruent with the tissue-specific patterns of damage 
observed (28, 29, 55).  Finally, confusion regarding the role of autoantibodies in 
scleroderma is confounded by the ~10% of patients with scleroderma in the absence of 
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any known autoantibodies.  Whereas the clinical features of these patients suggest an 
autoimmune mechanism similar to that of the majority of scleroderma patients, 
speculation remains about whether or not autoantibody negative scleroderma might 
constitute an entirely different disease process. Although current evidence does not point 
to a pathogenic role for autoantibodies in scleroderma, their tight associations with 
clinical phenotypes suggest that these antibodies may mark the specificities of cytotoxic 
T cells and other cell mediated responses playing an important role in pathogenesis.   
 
Cancer and scleroderma 
As in other systemic autoimmune diseases, scleroderma is associated with an 
increased risk of cancer.  For scleroderma patients, lung cancer is the most common 
malignancy, but there is also a striking temporal association in some cases between the 
diagnoses of breast cancer and scleroderma (23, 24).  Interestingly, in a study of 23 
scleroderma patients who had also been diagnosed with cancer, a tight temporal 
relationship between malignancy diagnosis and the onset of scleroderma was found in 
patients positive for anti-RNA Pol I/III antibodies, but this relationship was not seen in 
patients positive for anti-topoisomerase 1 and anti-centromere antibodies.  Moreover, the 
tumors from the scleroderma patients positive for anti-RNA Pol I/III antibodies were 
found to highly express RNA Pol III whereas tumors from scleroderma patients negative 
for this antibody and healthy tissue controls did not (56).  Recent work has extended this 
observation by demonstrating the presence of either mutations or loss of heterozygosity 
of the POLR3A gene encoding the RPC1 subunit of RNA polymerase III in the cancers of 
some of these patients with scleroderma and anti-RNA Pol III antibodies (57).   
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Moreover, for a subset of these patients, CD4 T cells reactive to peptides containing the 
patient specific mutations as well as wild type RPC1 peptides were detectable, suggesting 
that a somatic mutation within a cancer can result in the maturation of autoreactive 
lymphocytes and high titer autoantibodies specifically associated with scleroderma. 
 
Progenitor cells may link cancer and systemic autoimmune disease 
Several observations made by the Rosen lab in the study of another systemic 
autoimmune disease, autoimmune myositis, have led a compelling model of systemic 
autoimmunity:  first, regenerating muscle fibers in myositis patients express high levels 
of autoantigens whereas the levels are much lower in fully differentiated, healthy muscle; 
second, antigen expression correlates with myoblast differentiation status in vitro; and 
finally, cancers associated with myositis also express high levels of these autoantigens 
while the corresponding healthy tissues do not (13).  These data suggest that in myositis, 
an anti-cancer immune response may be misdirected at muscle progenitor cells, resulting 
in immune mediated injury of regenerating muscle tissue.  The shared features of 
systemic autoimmune diseases, including their associations with autoantibodies and 
cancer as well as the presence of a self-amplifying cycle of tissue destruction and 
immune system activation with a failure of homeostatic tissue repair, lead us to suspect 
that this model may be applicable to other systemic autoimmune diseases, including 
scleroderma. 
The hypothesis that an anti-tumor immune response may target proteins also 
expressed by progenitor cells is supported by the phenotypic overlap between cancer cells 
and tissue progenitors. Shared functions, including cellular homing and migration, are 
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critical in the processes of development, tissue repair, and cancer metastasis, all of which 
utilize similar mechanisms to target stem cells to their respective destinations (58).  
Additionally, two independent studies founds embryonic stem cell-like (ESC-like) 
expression signatures in human cancers, one showing that the ESC-like signature in 
epithelial cancers strongly predicted metastasis and death (59) while the other found ESC 
genes are more frequently overexpressed in several types of poorly differentiated tumors 
(60).  Whereas the connection between stem cells and cancer is an area of ongoing 
investigation (61), current evidence highlighting the similarities in cell phenotypes and 
gene expression patterns lend support to the idea that an antitumor immune response may 
target molecules also expressed by tissue progenitor cells. 
 
A model of mechanism in scleroderma 
In scleroderma, we hypothesized that an anti-tumor immune response is 
misdirected at target tissue progenitor cells, possibly those involved in the repair of 
damaged blood vessels (Figure 8).  Historically, experiments seeking to identify the 
targets of scleroderma autoantibodies have used tractable cell lines such as HeLa 
(cervical cancer derived) or Hep2 (laryngeal carcinoma derived) cells as the antigen 
source (Figure 1).  In contrast, we propose that by using antigen sources that approximate 
the target of the immune response, we will discover novel and mechanistically relevant 
autoantigens.   
 
Defining a disease relevant antigen source in scleroderma 
Stem cells are distinguished from other cell types by unlimited self renewal 
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capabilities and the capacity to differentiate into more specialized progenitors and cell 
lineages.  Resident stem cells contribute to the homeostasis and regeneration of tissues 
derived from all three germ layers.  Bone marrow derived stem cells are also able to 
migrate to distant tissues where local niches may specify differentiation into tissue 
specific progenitors (62).  Because the target of the immune response in scleroderma is 
unknown, this investigation started with undifferentiated human embryonic stem cells 
(ES), which are capable of differentiating into any cell type in the human body.  When 
these cells are cultured in suspension in the absence of anti-differentiation factors, they 
spontaneously differentiate and form three-dimensional aggregates called embryoid 
bodies (EBs) (63, 64).  These EBs are heterogeneous, but contain tissues from all three 
germ layers that are spatially patterned and grossly recapitulate the earliest stages of 
embryonic development (65).  Since the differentiation of these embryoid bodies is not 
directed down any particular path, they should provide an unbiased source of proteins 
expressed by many cell types at many stages of differentiation, likely enabling the 
detection of relevant scleroderma progenitor antigens.   
In this chapter, we demonstrate that novel scleroderma autoantigens are detected 
in lysates of differentiating human embryonic stem cells using scleroderma patient sera as 
probes.  We also demonstrate that these differentiating stem cells are particularly 
enriched for proteins targeted by autoantibodies in patients previously considered 
autoantibody negative.  Further, we were able to identify keratin 8 and fetuin A as two 
novel autoantigens targeted by “autoantibody negative” patients.  Finally, we demonstrate 
that immunofluorescence of embryoid bodies can be used to colocalize the expression of 
autoantigens and lineage markers to aid in the identification of specific cell lineages 
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expressing high levels of autoantigens, potentially allowing the identification of the true 




Materials and methods 
 
Human sera 
Frozen aliquots of de-identified sera from 147 scleroderma patients were obtained 
during routine blood draws at the Johns Hopkins University Scleroderma Center after 
written informed consent.  All patients either met American College of Rheumatology 
criteria for SSc (66), or had at least three of five features of CREST syndrome (calcinosis, 
Raynaud’s phenomenon, esophageal dysmotility, sclerodactyly, telangectasias), or had 
definite Raynaud’s phenomenon, abnormal scleroderma pattern nail fold capillaries, and 
the presence of a scleroderma specific autoantibody (anti-topo 1, ACA or anti-RNA 
polymerase III). Normal sera from 17 healthy donors were also used.  All samples were 
obtained, and studies were performed, in compliance with Institutional Review Board and 
Health Insurance Portability and Accountability Act regulations.  
 
Cell culture 
Human embryonic stem cell (ES) culture and embryoid body differentiation were 
performed as previously described (67).  Briefly, ES cells (WA-09; passage 39) were 
cultured on mouse embryonic fibroblasts (MEFs) in Dulbecco’s modified Eagle’s 
medium (DMEM)/F12 (GIBCO), supplemented with 20% KnockOut Serum 
Replacement (GIBCO), 0.1 mM b-mercaptoethanol, and six ng/ml of FGF-2.  Cells were 
passaged with six U/ml of dispase in ES media, washed, and replated at a dilution of 1:3–
1:5.  For embryoid body differentiation, undifferentiated ES colonies were resuspended 
in ES medium/20% fetal calf serum without bFGF and plated on poly-HEMA coated 
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plates to prevent attachment.  Cystic EBs emerged after five days in suspension and on 
day ten, ~80% of EBs were cystic.   
HeLa cells were cultured in Dulbecco’s modified eagle medium (DMEM; 
Invitrogen) low glucose with 10% HI FCS, 1% L-glutamine, and 1% 
penicillin/streptomycin at 37°C with 7.5% CO2.  K562 cells were cultured in RPMI 
supplemented with two mM glutamine and 10% FBS at 37°C in 5% CO2.   U2OS cells 
were cultured in McCoy’s 5A media supplemented with 1% L-glutamine, 10% HI FCS, 
and 1% penicillin/streptomycin at 37°C in 5% CO2.  HEK293 cells were cultured in 
DMEM (Invitrogen) high glucose with 10% HI FCS, 1% L-glutamine, and 1% 
penicillin/streptomycin at 37°C with 5% CO2.  Jurkat cells were cultured in RPMI 1640 




All steps of lysate preparation for all cell types were performed on ice.  For 
adherent cells (including undifferentiated ES, HeLa, U2OS, HEK293):  cells were 
washed with cold PBS (twice, with ten ml per plate) prior to being scraped into lysis 
buffer (NP40LB) (1% Nonident P40 (NP40); 20 mM Tris pH 7.4; 150 mM NaCl; one 
mM EDTA) containing a protease inhibitor cocktail (PIs) (pepstatin, antipain, leupeptin, 
and phenylmethylsulfonyl fluoride) using approximately one ml per every two to three 
plates, depending on cell density.  All lysates were combined, vortexed, and aliquoted 
(500 μl per tube) for storage at -80°C.   
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For EB lysate preparation: cultures were transferred into 50 ml conicals and spun 
at 1500 rpm for five minutes at 5°C.  Pellets were pooled and washed with cold PBS 
(three times with 50 ml each), spinning as previous between washes.  EBs were lysed in 
NP40LB+PIs by sonication (three times, ten seconds each), aliquoted (500 μl/tube), and 
stored at -80°C.  For other suspension cells (K562, Jurkat): cultures were transferred into 
50 ml conicals and spun at 1500 rpm for five minutes at 5°C.  Pellets were pooled and 
washed with cold PBS (two times with 25 ml each), spinning as previous between 
washes.  Cells were lysed by resuspension in NP40LB+PIs, aliquoted (500 μl/tube), and 
stored at -80°C.  All lysates were diluted to working concentrations in gel application 
buffer (2% SDS; 4% glycerol; 40 mM Tris-HCl, pH 6.8; 0.002% bromophenol blue; 1% 
β-mercaptoethanol) and boiled for three minutes.   
 
Immunoblotting with commercial antibodies 
 Five μg/lane of each lysate was electrophoresed on seven cm 10% SDS-PAGE 
gels for 170 Vh, then transferred onto a nitrocellulose membrane at 100 volts for one 
hour.  Membranes were stained with Ponceau (0.3% w/v in 3% trichloroacetic acid) and 
washed with distilled H2O to identify molecular weight markers, followed by blocking in 
Tris buffered saline/Tween 20 (TBST; ten mM Tris-HCl, pH 7.4; 150 mM NaCl; 0.05% 
(v/v) Tween 20) with 5% (w/v) powdered milk for one hour at RT.  Membranes were 
then incubated in TBST/5% milk containing the appropriate primary antibody (at an 
antibody-dependent dilutions) overnight at 4°C; washed five times for five minutes each 
with TBST/5% milk; incubated with a 1:10,000 dilution of horseradish peroxidase 
(HRP)-conjugated secondary antibody (species specificity dependent on primary 
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antibody) in TBST/5% milk for one hour at RT; washed five times for five minutes each 
in cold TBST buffer; and developed using an ECL chemiluminescent reagent (Pierce).   
Primary antibodies and dilutions used include: rabbit polyclonal anti-Oct 4 
antibody (Abcam, ab19857) at 0.2 μg/ml; rabbit monoclonal anti-Nanog antibody (Cell 
Signaling Technologies, D73G4) at 1:2000;  mouse monoclonal anti-Tubulin beta-3 
antibody (Millipore, 05-559) at 1:1000; rabbit polyclonal anti-NCAD antibody (Abcam, 
ab12221) at 1:1000; mouse monoclonal anti-CD31 antibody (DAKO, M0823) at 1:500; 
mouse monoclonal anti-beta actin antibody (Sigma, A2228, clone AC-74) at 1:20,000; 
rabbit polyclonal anti-B23 antibody (Covance) at 1:2000; rabbit polyclonal anti-
cytokeratin 8 antibody (Abcam, ab52949) at 1:10,000;  rat monoclonal anti-Hsc70 
antibody (Stressgen, SPA-815) at 1:200,000; goat polyclonal anti-fetuin A antibody 





Immunoblotting with patient sera 
Five μg/lane of each lysate was electrophoresed on seven cm 10% SDS-PAGE 
gels for 170 Vh, then transferred onto a nitrocellulose membrane at 100 volts for one 
hour.  Membranes were stained with Ponceau (0.3% w/v in 3% trichloroacetic acid) and 
washed with distilled H2O to identify molecular weight markers, followed by blocking 
for one hour at room temperature (RT) in 3% bovine serum albumin in wash buffer (WB) 
(ten mM Tris-HCl, pH 7.6; 0.5% NP40; 150 mM NaCl).  Membranes were then 
incubated with patient serum diluted in WB (1:5000) for one hour at RT.  After extensive 
washing with WB  (five times for five minutes each), membranes were subsequently 
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incubated with a horseradish peroxidase-conjugated goat anti-human IgG secondary 
antibody (Jackson Immunoresearch) at 1:10,000 dilution in WB for one hour.  
Membranes were then washed as above and incubated with enhanced chemiluminescent 
reagent (Pierce) followed by exposure to X-ray film. 
 
2-Dimensional (2D) electrophoresis 
For 2D electrophoresis, lysates were prepared in one of two ways: (i) cells from 
culture were washed twice with ten ml each cold PBS followed by washing twice with 
ten ml each cold [ten mM Tris HCl pH 7.4/205 mM Sucrose] and lysed directly into 
isoelectric focusing (IEF) buffer [eight M urea, two M thiourea, 4% CHAPS, 1% 
dithiothreitol (DTT) and protease inhibitors]; or (ii) lysates previously made in NP40LB 
were precipitated by TCA/acetone [briefly, a 1:1 volume of cold 20% trichloroacetic acid 
(TCA) was added to the lysate, followed by a 30 minute incubation on ice, pelleting at 
max speed 4°C for 15 minutes, supernatant removed, pellet washed with one ml ice cold 
acetone, repeated spin at max speed 4°C for 15 minutes, supernatant removed and pellet 
dried at RT] and resuspended in IEF buffer.    First dimension focusing was performed 
using Bio-Rad ReadyStrip immobilized pH gradient (IPG) Strips and Protean IEF Cell 
per manufacturer’s instructions.   Seven cm IEF strips were used to determine the 
optimum pH range for the protein of interest while 17 cm IEF strips were used for 
sequencing.  Briefly, each seven cm IEF strip was loaded with 130 μl consisting of 100 
μg lysate, 1.5% 2-hydroxyethyl disulfide, 0.1% bromophenol blue and 0.4% ampholytes 
(pH dependent on IEF strip pH range).  For 17 cm strips, 300 μg lysate was used in a 
total volume of 300 μl.  Up to 12 IEF strips can be run simultaneously; these can 
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subsequently be processed immediately for the second dimension gel (see below), or they 
can be stored at -80°C.  Prior to running the second dimension gels, IEF strips were 
incubated for 20 minutes at RT in ten mg/ml dithiothreitol, followed by 20 minutes in 25 
mg/ml iodoacetamide, both in equilibration buffer (six M urea; 0.375 M Tris-HCl, pH 
8.8; 2% SDS; 20% glycerol).  IEF strips were then loaded onto 10% SDS PAGE gels (16 
cm or seven cm gels, depending on the size of the IPG strips), covered with 1% low melt 
agarose (Promega) and electrophoresed as described above (16 cm gels were 
electrophoresed for 850 volt hours, and transferred onto nitrocellulose membranes for 
four hours at 400 mA).  To ensure consistency, IEF strips run in parallel were used for 
2D immunoblotting and corresponding protein sequencing experiments.   
 
2D immunoblotting and antigen localization 
2D gels were transferred to nitrocellulose membranes, stained with Ponceau to 
visualize resolved protein spots, and scanned at high resolution for alignment with the 
subsequent immunoblots.  Immunoblots were performed as described.  During X-ray film 
exposure, precise documentation of the membrane perimeter on the film is critical for 
subsequent alignment of the exposed film with a printout of the Ponceau scan.  This 
enables the immunoblotted spot of interest to be aligned with the corresponding Ponceau-
stained protein spot.  Once the protein of interest is located on the Ponceau scan, nearby 
spot patterns can be used for orientation to find the same spot on the preparative gel for 





Preparative SDS-PAGE second dimension gels were made using solutions and 
procedures that minimize exposure to airborne contaminants.  All glassware and 
equipment were only used for proteomics experiments and were washed twice with 0.1% 
SDS (w/v) followed by extensive rinsing with ultrapure distilled water and 100% 
methanol to minimize protein contamination.  After performing first and second 
dimension gel runs as described, gels were fixed in destain (14% v/v acetic acid; 24% v/v 
methanol) for 15 minutes, incubated for one hour in Gel Code Blue Stain (Thermo 
Scientific) and then destained in ultrapure distilled water for two to four hours. Destained 
gels were placed on a light box to facilitate visualization of stained protein spots, and gel 
plugs containing the protein spot of interest and a nearby “blank” gel plug containing no 
visible protein were carefully removed from the preparative gel using a sterile pipette tip. 
The gel plugs were immediately washed twice in 50% methanol for ten minutes each 
with shaking and stored at -20°C.  The remaining preparative gel was washed three times 
for five minutes each in running buffer (25 mM Tris-HCl; 200 mM glycine; 0.1% (w/v) 
SDS), and proteins were transferred to nitrocellulose membrane for immunoblotting to 
verify successful plucking.  Gel plugs confirmed to contain the protein of interest were 
sent to the Johns Hopkins Mass Spectrometry and Proteomics Facility for liquid 
chromatography tandem mass spectrometry (LC/MS/MS) peptide sequencing. 
 
Antigen identity confirmation 
Solubility fractioning – 50 μg of cell lysates were brought up to 90 μl in 
NP40LB/PIs and solubilized by sonication twice for ten seconds each (amplitude 3-4) 
followed by vortexing.  The insoluble lysate fractions were collected by centrifugation at 
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4°C for 30 minutes at max speed (13.2 rpm) in tabletop centrifuge and supernatants 
containing soluble fractions were moved to a new tube.  Ten μl of 5x GAB/βMe was 
added to each soluble fraction.  Insoluble fractions were resuspended in 90 μl 
NP40LB/PIs by sonication twice for ten seconds each (amplitude 3-4) followed by 
vortexing and ten μl of 5x GAB/βMe was added.  Samples were boiled three minutes and 
11 μl was loaded per lane for immunoblotting. 
2D membrane stripping – Following immunoblot with commercial (non-human) 
primary antibody, membrane was washed five minutes with TBST then stripped in 0.1 M 
glycine, pH 2.7, for seven minutes at 37°C following by shaking at RT for seven minutes.  
Membrane was then washed twice for five minutes each with WB/azide, then washed 
three times for five minutes each with WB(-) azide.  To confirm stripping, membrane was 
incubated in ECL reagent for five minutes and used to expose X-ray film for five to ten 
minutes.  After antibody stripping was confirmed, membrane was washed for five 
minutes in WB(-) azide, blocked 30 minutes in WB/azide/3% BSA and blotted with 
human serum as previously described. 
 Overlay program – Digital overlay of 2D immunoblots was performed using a 
computer program designed specifically for this purpose by Steven J. Handy (Senior 
Software Engineer, The Johns Hopkins University).  This program allows the import of 
scanned X-ray films, which can then be modified (scaling, transparency, and color 
tinting) to allow digital overlay of immunoblot images.  Precise alignment of images was 
possible through careful recording of the edges of the nitrocellulose membrane on the X-
ray film as well as the positions of the molecular weight markers. 
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Transfection – U2OS and HEK293 cells were transfected with pKeratin 8 
(Origene) and pFetuin A (Origene) respectively using FuGene 6 (Roche) per 
manufacturer’s instructions.  Mock transfected cells were used as negative controls. 
 Non-reduced lysate preparation – For preparation of non-reduced gel samples, 
lysates were diluted to working concentrations in gel application buffer (2% SDS; 4% 
glycerol; 40 mM Tris-HCl, pH 6.8; 0.002% bromophenol blue) without β-
mercaptoethanol and boiled for three minutes.  Reduced and non-reduced EB lysates 
were resolved on a 7.5% SDS-PAGE gel and immunoblotted as previously described. 
Deglycosylation –  Deglycosylation of EB lysates was performed using a Protein 
Deglycosylation Mix (New England Biolabs, P60395) containing PNGase F, O-




All steps were performed gently to preserve morphology.  Embryoid bodies from 
culture were pelleted at 500 rpm for two minutes at RT.  The media was removed and the 
pellet was washed in five ml cold PBS by inversion.  The EBs were spun as previous, 
PBS removed, and pellet fixed in five ml 2% PLP (2% paraformaldehyde, 0.075 M L-
Lysine, 0.0375 M PO4, 0.01 M Na-m-periodate) for a total of 30 minutes at RT with 
occasional inversion.  PLP was removed following a spin as previous and fixation was 
quenched by addition of five ml fresh NH4Cl (50 mM NH4Cl in PBS, made right before 
use), followed by inversion.  The NH4Cl was removed following a spin as previous and 
~20 μl 2% low melt agarose (in H2O +colorant, i.e. ferritin; @65°C) was added and 
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allowed to partially solidify at room temperature for two minutes.  For cryoprotection, ten 
ml cold [0.5 M sucrose in 0.1 M NaPO4, pH 7.4] was added and complete solidification 
was performed at 4°C for four to eighteen hours.  The agarose plug was transferred to a 
cryomold containing TBS freezing medium and covered fully with additional freezing 
medium followed by immersion into 2-methylbutane cooled with dry ice.  After freezing 
for two to five minutes the cryomold was dried on dry ice followed by storage at -80°C.  
Ten μm sections were cut using a cryostat at -20°C and sections were placed on lysine 
coated glass microscopy slides (stored at -20°C). 
 
Immunofluorescence 
Tissue sections were encircled with a hydrophobic pen, then fixed and 
permeabilized by dipping slides into ice cold acetone for 30 seconds and immediately 
washed by immersion into PBS three times 30 seconds (without letting slides dry).  
Sections were blocked for one 1 hour at RT in 5% serum* in PBS (*using serum from 
same animal as the secondary antibody).  Primary antibodies were diluted in a final 
volume of 250 μl per slide (dilutions detailed below) in 5% serum* in PBS and spun at 
5000 rpm for five minutes before use.  Slides were incubated in primary antibody 
dilutions overnight at 4°C in a humidity chamber, then washed in PBS three times for ten 
minutes each without shaking.  Secondary antibodies were diluted 1:200 in 1% normal 
goat serum in PBS and spun at 5000 rpm for five minutes prior to adding 100 μl per slide 
and incubated for one hour at RT in the dark.  Slides were then washed in PBS three 
times for ten minutes each and, while still wet, one to two drops of Prolong Gold w/ 
DAPI (Life Technologies, P-36931) was added to each tissue section, covered with a 
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glass cover slip, allowed to set overnight at RT with minimal light exposure and store in 
the dark at 4°C.   
Primary antibodies and dilutions used include: rabbit polyclonal anti-Oct 4 
antibody (Abcam, ab19857) at 1:400; rabbit polyclonal anti-NCAD antibody (Abcam, 
ab12221) at 1:300; mouse monoclonal anti-Tubulin beta-3 antibody (Millipore, 05-559) 
at 1:300; anti-RNA polymerase III positive scleroderma patient serum at 1:1000; anti-
topoisomerase 1 positive scleroderma patient serum at 1:1000; mouse monoclonal anti-
CD31 antibody (DAKO, M0823) at 1:20.  Corresponding secondary antibodies specific 
for primary antibody species and conjugated with either Alexa Fluor 488 or Alexa Fluor 





Detection of novel scleroderma autoantigens in differentiating stem cells 
Undifferentiated human embryonic stem cells were allowed to differentiate 
spontaneously into three-dimensional embryoid bodies, which were harvested at various 
time points during differentiation.  With continued differentiation, the embryoid bodies 
increase in size and become increasingly cystic, with representative light microscopy 
images of an undifferentiated ES cell colony, and days three, seven, and ten of EB 
differentiation shown (Figure 9A-D respectively).  Differentiation is associated with 
down-regulation of the pluripotency markers Oct 4 and Nanog (Figure 9E), as well as up-
regulation of germ layer and lineage specific markers, including Tubulin beta-3 
(ectoderm), N-cadherin (NCAD) (mesoendoderm), and CD 31 (endothelial lineage) 
(Figure 9E).  Expression of scleroderma autoantigens (topo 1, snRNP70/U1-70K, and 
B23) were also evaluated in differentiating embryoid bodies.  Topo 1 and snRNP70 
followed similar expression patterns, with high expression in undifferentiated ES cells 
and low expression in differentiation days one through four, followed by increasing 
expression that plateaus around differentiation day ten (Figure 9E).  In contrast, B23 
expression levels are highest in undifferentiated and day one EBs, but also transiently 
drop around differentiation day four (Figure 9E).  In addition to undifferentiated ES cells, 
day ten EBs were chosen for subsequent screens based on increased expression of 
scleroderma autoantigens and the presence of a mixture of cell lineages, including cells 
expressing CD31, consistent with reports that EBs at this stage are enriched for vascular 
progenitor cells (68).  
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Scleroderma patient sera were screened by immunoblotting for high titer 
autoantibodies targeting proteins expressed in undifferentiated human embryonic stem 
cells or day ten human embryoid bodies, with HeLa cells as a control for the detection of 
ubiquitously expressed proteins (Figure 10A).  Over one third of 89 randomly selected 
scleroderma sera tested contained autoantibodies targeting proteins exclusively present in 
undifferentiated ES or day ten EB lysates (Table 3).  As a more stringent test of our 
hypothesis, we next screened the sera of 35 patients clinically determined to be ANA 
negative.  Strikingly, over half had autoantibodies targeting proteins expressed in 
undifferentiated ES cells or day ten EBs that are not expressed by HeLa cells (Figure 
10B).  Finally, 23 patients with scleroderma and cancer were screened and many were 
found to have autoantibodies targeting ES or EB specific proteins (data not shown, Table 
3).  In contrast, no high titer autoantibodies were detected in 17 healthy control sera 
tested, a representative example is denoted (HC) in Figure 10A.  Patient sera were next 
used as probes in the identification of the proteins targeted by autoantibodies in patients 
previously considered autoantibody negative. 
 
Identification of keratin 8 as a novel scleroderma autoantigen 
The identification of the ~50 kDa protein targeted by serum autoantibodies in 
patient SSc-3 (Figure 10B) using the previously described triangulation strategy is 
illustrated (Figure 11).  This antigen was of particular interest because it is targeted by a 
patient previously determined to be negative for antinuclear autoantibodies and the 
targeted protein was not expressed by several commonly used cell lines, including HeLa 
(cervical cancer derived), Jurkat (T lymphocyte derived), U2OS (osteosarcoma derived), 
60 
 
and K562 (erythroleukemia derived) (Figure 11A).  The protein was localized on a 2D 
gel (pH 3-10) by immunoblotting (Figure 11B) and the location of the protein was noted 
on the corresponding Ponceau stain (data not shown).  An identical gel was stained with 
colloidal blue and multiple spots containing the protein of interested were plucked from 
the gel (Figure 11B & 11C insets) and confirmed to contain the protein of interest by 
post-pluck immunoblotting with SSc-3 serum (Figure 11C).  Three of the plucked gel 
plugs were sent for separate LC/MS/MS peptide sequencing.   
After subtracting contaminants sequenced from a nearby “blank” gel plug, the 
only protein detected in all three gel plugs was keratin 8 (KRT8).  The significance of 
this finding was initially unclear because keratins are the most common contaminants 
detected by LC/MS/MS peptide sequencing (69).   To determine if the SSc-3 targeted 
antigen could be a keratin, day ten EB lysates were separated into soluble and insoluble 
fractions and immunoblotted with SSc-3 serum (Figure 11 D).  Whereas vinculin was 
localized to the soluble fraction as expected, the SSc-3 targeted protein localized to the 
insoluble fraction, as expected for a keratin.   
Confirmation of the identity of this protein was pursued using multiple methods.  
First, EB lysate resolved by 2D gel (pH 3-10) was immunoblotted with a rabbit 
polyclonal anti-cytokeratin 8 antibody (Figure 12A).  The membrane was subsequently 
stripped of all bound antibody (Figure 12B) and re-probed with the SSc-3 human serum 
(Figure 12C).  The alignment of the two blots confirms precise overlap of the proteins 
bound by the polyclonal anti-keratin 8 antibody and SSc-3 patient serum autoantibodies 
(Figure 12D).  A second method of confirmation was attempted using 
35
S-methionine 
labeled keratin 8 (
35
S-KRT8) generated by IVTT using keratin 8 cDNA.   While the anti-
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keratin 8 commercial antibody was able to immunoprecipitate the recombinant 
35
S-
KRT8, the SSc-3 patient serum was not (data not shown).  To assess SSc-3 antibody 
recognition of keratin 8 in a more physiological state, a plasmid expressing keratin 8 
cDNA (pKeratin 8) was transiently transfected into U2OS osteosarcoma cells (Figure 
12E).  Immunoblotting with the polyclonal anti-cytokeratin 8 antibody demonstrated the 
absence of keratin 8 in mock transfected cells (-) and robust expression of keratin 8 in the 
transfected cells (+).  The SSc-3 patient serum also recognized the same 50 kDA only in 
the transfected cells, in contrast to no detection by a healthy control serum.  Lysates from 
U2OS cells transiently expressing keratin 8 were separated into soluble and insoluble 
fractions and used to screen 63 additional scleroderma sera for the presence of anti-
keratin 8 antibodies by immunoblotting (data not shown).  Only 1/63 scleroderma 
patients was positive for anti-keratin 8 antibodies by immunoblotting, compared to 0/20 
healthy controls.  Both the prototype and screen anti-keratin 8 positive patients have the 
limited form of scleroderma with mild disease. 
 
Identification of fetuin A as a novel scleroderma autoantigen 
The identification of the antigens targeted by autoantibodies in patient SSc-4 was 
pursued because this patient had an intriguing specificity pattern (Figure 10B).  Two 
similarly sized proteins are targeted, the larger of which is ~70 kDa and expressed 
equally in all cells tested (Figure 10B open arrow) and the other is ~68 kDa and faintly 
detected in HeLa cells, absent in undifferentiated ES cells, and strongly upregulated in 
day ten EBs (Figure 10B, black arrow).  This patient also has a history of cancer and is 
clinically negative for known SSc autoantibodies.   
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Although these two proteins were difficult to separate by size alone on a 1D gel, 
they demonstrated substantially different isoelectric points (pIs) when separated on a 2D 
gel with a pH 3-10 gradient (Figure 13A), with the ~68 kDa EB specific antigen having a 
pI near three (black arrow, lower left inset) and the ~70 kDa ubiquitously expressed 
protein having a pI near 5.5 (open arrow, lower right inset).  In addition, both of these 
proteins demonstrate multiple horizontally separated isoforms on the 2D gel, likely due to 
post translational modifications that alter the pI without a significant change in protein 
size.  The protein spots corresponding to the immunoblot signal were identified and 
plucked from an identically run gel code blue stained gel (Figure 13B) and correct spot 
selection was confirmed (Figure 13C) as previously described. 
The ~70 kDa commonly expressed protein band was identified by LC/MS/MS 
sequencing to be heat shock cognate 71 kDA protein (HSC70), which was confirmed by 
precise overlay of identically run 2D gels immunoblotted with a commercial anti-HSC70 
antibody and SSc-4 patient serum (Figure 13D).   
The leading candidate for the acidic 68 kDa antigen expressed in day ten EBs 
after LC/MS/MS sequencing was fetuin A, a protein normally synthesized in the liver and 
secreted into the plasma.  This protein undergoes multiple post-translational 
modifications prior to secretion, including cleavage into two peptide chains (of 282 aa 
and 27 aa) held together by a disulfide bond and extensive glycosylation of the larger 
chain A.  Based on the size, pI, and 2D pattern of the antigen of interest (and that lysates 
were regularly reduced prior to resolution), it is likely that the 68 kDa band represents the 
glycosylated form of the 282 aa A chain of fetuin A, predicted to be only 30 kDa in the 
absence of glycosylation.   
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Several approaches were taken to confirm that the 68 kDa SSc-4 antigen was 
fetuin A.  First, reduced and non-reduced lysates were probed with a polyclonal anti-
fetuin A antibody and SSc-4 serum (Figure 13E).  While the 68 kDa protein (black arrow 
in SSc-4 blot) is present in the reduced lysates (+) as previously shown, the protein is 
absent in the non-reduced lysates (-).  As expected, in the SSc-4 immunoblot, the protein 
band corresponding to HSC70 (Figure 13E, open arrow) remains unchanged in the 
absence of reduction. 
Deglycosylation of the EB lysates prior to immunoblotting also confirmed a 
parallel decrease in band size in the deglycosylated lysates (Figure 13F (+)) with the 
polyclonal anti-fetuin A antibody (upper panel) and the SSc-4 serum (lower pane, black 
arrows).  Notably, deglycosylation did not impact the ability of the patient autoantibodies 
to bind fetuin A.  Immunoprecipitation of 
35
S-methionine labeled fetuin A (
35
S-FETA) 
generated by IVTT using fetuin A cDNA was also attempted.  Although the polyclonal 
anti-fetuin A antibody was able to IP the 
35
S-FETA, the SSc-4 patient serum was not 
(data not shown).  Finally, a plasmid containing fetuin A cDNA (pFetuin A) was 
transiently transfected into the HEK293 (human embryonic kidney derived) cell line.  
Both the commercial anti-fetuin A antibody and SSc-4 bound the 68 kDa protein 
exclusively in the transfected (+) cells, with no protein of this size detected in the mock 
transfected control (-) (Figure 13G). 
 To determine the prevalence and possible clinical relevance of the newly 
discovered anti-fetuin A autoantibodies, 63 randomly selected scleroderma patient sera 
were screened by immunoblotting lysates from HEK293 cells transfected with either a 
plasmid containing fetuin A cDNA or a mock transfected control (data not shown).  Six 
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patients were positive for anti-fetuin A autoantibodies by immunoblotting (9.5%), with 
5/6 having the diffuse form of scleroderma.  In contrast 0/20 healthy controls had anti-
fetuin A autoantibodies. 
 
Localization of autoantigen expression by indirect immunofluorescence 
 Finally, to determine which cell lineages within the heterogeneous embryoid 
bodies are expressing high levels of scleroderma autoantigens, EBs at various stages of 
differentiating were carefully embedded to preserve their 3-dimensional structure and 
antigen expression was detected using indirect immunofluorescence (Figure 14).  By day 
seven of differentiation, the EBs demonstrate a consistent expression pattern of germ 
layer markers, with undifferentiated (Oct 4 positive) cells remaining at the periphery 
(Figure 14A), and mesoendodermal (NCAD positive) cells and ectodermal (Tubulin beta-
3 positive) cells in the center of the EB (Figures 14B and 14C respectively).  
Colocalization of RNA polymerase III expression with Oct 4 revealed that RNA 
polymerase III is upregulated in cells expressing Oct 4 in day seven EBs (Figure 14D).  
In contrast, topoisomerase 1 expression levels appeared relatively uniform in day seven 
EBs and are not upregulated in Oct 4 expressing cells (Figure 14E).  Finally, since we 
hypothesized that scleroderma autoantigens may be upregulated in blood vessel 
progenitors, we sought to colocalize expression of RNA polymerase III and 
topoisomerase 1 with expression of the early vessel marker CD31 in day 12 EBs.  The 
nuclear staining of RNA pol III (Figure 12F, red) was not upregulated in the cells 
expressing the membrane protein CD 31 (Figure 12F, green).  However, it does appear 
that CD31 negative cells near the site of blood vessel formation show higher expression 
65 
 
of RNA polymerase III than surrounding cells (Figure 14F, arrows).  In contrast, there is 
no apparent association of topoisomerase 1 expression (Figure 14G, red) with nascent 
vessels expressing CD31 (Figure 14G, green) in day 12 EBs.  These data demonstrate 
differential expression of the scleroderma autoantigen RNA polymerase III in 
differentiating cells within embryoid bodies, with increased expression seen in 
undifferentiated or early ectodermal Oct 4 positive cells in day seven EBs and in CD31 





This work has shown that roughly one third of randomly selected scleroderma 
sera and a striking 60% of ANA negative scleroderma sera contain autoantibodies that 
recognize antigens uniquely expressed in undifferentiated stem cells or differentiating 
day ten embryoid bodies.  Moreover, none of these proteins are targeted by healthy 
control sera and they are not expressed in HeLa cells, which are classically used for 
antigen identification.  These data indicate that many antigens important in scleroderma 
autoimmunity remain to be identified.  Moreover, the discovery of many proteins targeted 
by high titer autoantibodies in ANA negative patient sera confirm that autoimmunity is a 
prominent aspect of their disease.   Finally, the abundance of novel antigens detected 
specifically in ES or EB cells strongly supports the hypothesis that stem and progenitor 
cells are improved approximations for the true target(s) of the autoimmune response in 
scleroderma.   
Keratin 8 was identified as a novel autoantigen in scleroderma.  Current 
knowledge of the function of keratin 8 suggests many intriguing mechanistic possibilities 
for the role of anti-keratin 8 autoantibodies in scleroderma.  For example, keratin 8 is a 
clinically important marker of epithelial cancers (70, 71).  Moreover, the C terminus of 
keratin 8 penetrates the cell membrane and has been identified as a major plasminogen 
receptor on the surface of breast cancer cells, facilitating plasmin activation and the 
degradation of basement membranes and extracellular matrix components.  Interestingly, 
plasminogen binding and activation can be inhibited by the presence of a monoclonal 
antibody generated against the C-terminus of keratin 8 (72).  These data suggest that the 
generation of anti-keratin 8 autoantibodies would be potentially effective component of 
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an anti-tumor immune response.  Evaluation of patient anti-keratin 8 autoantibodies for 
C-terminal epitope specificity and the ability to block fibrin activation by cancer cells 
would support the model that these autoantibodies are generated during an anti-tumor 
immune response.   
In addition to its role in cancer, keratin 8 has also been implicated in the injury 
response of vascular smooth muscle cells (73) and epithelial cell resistance to stress and 
apoptosis (74, 75).  A role in the response to tissue injury may lead to high levels of 
keratin 8 expression at sites of active disease in scleroderma.  Moreover, the presence of 
anti-keratin 8 antibodies with the capacity to block the activation of fibrinogen in the 
context of tissue repair could result in a profibrotic environment like that seen in 
scleroderma.  Comparing the levels of keratin 8 expression in diseased and healthy 
tissues may lead to important insights regarding the role of this autoantigen in 
scleroderma pathogenesis. 
More extensive screening for the presence of anti-keratin 8 antibodies will be 
necessary to determine their prevalence, specificity, and any clinical phenotype 
associations.  Interestingly, the patient anti-keratin 8 autoantibodies were not able to 
immunoprecipitate a recombinantly expressed form of the protein, which may suggest 
that post-translational modifications may be important in recognition of this antigen.  In 
fact, keratin 8 undergoes extensive phosphorylation, acetylation (76, 77), and O-linked N-
acetylglucosamine modification (78), which could be relevant to a unique function in 
progenitor or cancer cells as well as antibody recognition.  Whereas radiolabeling cells 
transfected with keratin 8 may allow more extensive screening by immunoprecipitation, a 
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method that is more sensitive than immunoblotting, it may also be interesting to explore 
the potential modification dependent recognition of this protein by patient autoantibodies. 
The identification of fetuin A (also known as α2-HS glycoprotein) as a target of 
scleroderma patient autoantibodies could be another exciting discovery.  This protein is 
secreted by the liver into the plasma, is found at much higher levels in fetal serum than 
adult serum, and is a negative acute phase reactant (79).  Fetuin A is also a major 
component of fetal bovine serum and has been implicated as the key molecule facilitating 
cell attachment and growth in tissue culture (80, 81). 
Fetuin A has also been implicated as a tumor antigen.  In a mouse model of 
lymphoma, comparison of serum antibodies found that mice immunized with a 
tumorigenic lymphoma line developed anti-fetuin A antibodies whereas mice immunized 
with a non-tumorigenic variant line did not, despite the fact that fetuin A expression 
levels are similar in both cell lines.  These data suggest that a modification of fetuin A 
associated with tumorigenicity is also capable of specifically initiating an anti-fetuin A 
immune response (82).   In a mouse model of breast cancer, the absence of fetuin A 
decreases the incidence of breast cancer and increases tumor latency (83), while fetuin A 
was also found to promote the attachment and growth of human breast cancer cells in 
vitro (80).  Moreover, anti-fetuin A antibodies have been suggested as a potential 
biomarker in breast cancer screening (84).  Given the temporal relationship between the 
onset of breast cancer and scleroderma in some patients (85), these data support a role for 
fetuin A as a tumor antigen that may be targeted by autoantibodies in scleroderma.  
Examining expression levels and post-translational modifications of fetuin A in 
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scleroderma disease tissues and scleroderma associated tumors may provide insight into 
the pathogenic mechanisms underlying this disease.   
Interestingly, a fetuin A knockout mouse model demonstrates an important role 
for this protein in the inhibition of ectopic calcification (86) and there is evidence that 
direct binding of calcium and phosphate to an array of acidic amino acid residues in one 
domain of the protein prevents basic calcium phosphate precipitation (87).  This is of 
particular relevance to scleroderma because subcutaneous calcium deposition, known as 
calcinosis, can be a prominent feature of disease.  If the presence of anti-fetuin A 
autoantibodies inhibits the ability of fetuin A to bind calcium, this could be the first hint 
at a mechanism for calcinosis.   Looking at the correlation of calcinosis and anti-fetuin A 
autoantibodies among scleroderma patients will be useful in determining whether or not 
these antibodies play a pathogenic role. 
Given the many potential roles that fetuin A may play in the pathogenesis of 
scleroderma, we are eager to explore the prevalence and clinical associations of anti-
fetuin A antibodies in our scleroderma cohort.  Initial experiments indicate that the serum 
antibodies are not able to immunoprecipitate the IVTT generated protein, indicating that 
post-translational modifications may be necessary for recognition.  Immunoblotting or 
immunoprecipitation of transfected lysates will potentially allow a screen of many 
patients and normal controls to determine the significance of this autoantibody in 
scleroderma.   
We demonstrate that expression of known scleroderma autoantigens may be 
differentially regulated during stem cell differentiation.  Whereas most scleroderma 
autoantigens identified to date perform necessary cellular functions and are thus 
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ubiquitously expressed, characterization of these proteins during stem cell differentiation 
has not been studied to our knowledge. Characterization of autoantigen levels during 
differentiation of human embryonic stem cells is challenging because not all scleroderma 
autoantigens are amenable to immunoblotting (including RNA polymerase III and 
centromere A proteins).  In addition, EBs are heterogeneous mixtures of cell types at 
various stages of differentiation, such that upregulation of antigen expression by a given 
cell type within such a mixture may not be consistently detected by immunoblots of EB 
lysates.  Detection of antigen expression on an individual cell level by indirect 
immunofluorescence may be useful in identifying relatively higher levels of antigen 
expression in particular lineages within these EBs, as our preliminary data suggest.  
Additional studies colocalizing autoantigen expression and cell lineage markers may 
provide critical insights regarding the true target of the immune response in 
scleroderma. These studies will also be greatly enhanced by characterization of cells 
expressing high levels of autoantigens in the target tissues from scleroderma patients – 
studies that are currently being pursued by the Rosen lab.   
This investigation is the first to demonstrate the targeting of progenitor specific 
proteins by autoantibodies in scleroderma, including the discovery of two novel 
autoantigens, keratin 8 and fetuin A.  Our data also suggest that well established targets 
in scleroderma, including RNA polymerase III, are differentially regulated during stem 
cell differentiation.  Together, these data support the hypothesis that differentiating 





Table 3:  Immunoblot screen for antibodies targeting proteins expressed by 
undifferentiated human embryonic stem cells and differentiating embryoid bodies. 
 
Serum Screened                  Total (n)            Positive
a   
n (%)  
Scleroderma   89    32 (36%)  
ANA Negative SSc  35    21 (60%) 
SSc-Cancer    23    8 (35%)  
Total     147    61 (41%)  
Healthy Controls  17    0 (0%)   
 
a
 Positive for antibodies binding ≥ 1 protein in ES and/or EB lysates in the absence of a 
corresponding protein in HeLa lysate 
SSc = Scleroderma; ANA = anti-nuclear antibodies; ES = undifferentiated human 






Figure 8:  A model for the mechanism of autoimmunity in scleroderma.  A. The 
immune system combats a nascent tumor resulting in mature lymphocytes specific for 
self-antigens expressed by the neoplasm, which may include proteins that are normally 
only expressed by stem/progenitor cells.  B. Tissue injury results in the expansion and 
differentiation of stem and progenitor cells involved in the tissue repair process.  In the 
presence of auto-reactive lymphocytes, progenitors expressing previously sensitized 
tumor antigens are targeted for destruction by the immune system.  The failure of healthy 
tissue repair leads to a feed forward cycle of immune mediated tissue damage and 
sustained stimulation of the immune system by antigen expressing progenitor cells 




Figure 9:  Differentiation of human embryonic stem cells into embryoid bodies.  
Light micrographs of adherent, undifferentiated ES colony (A), and day three (B), day 
seven (C), and day ten (D) EBs in suspension.  There is significant heterogeneity in the 
size and shape of EBs throughout differentiation, with both size and cystic content 
increasing with prolonged differentiation.  (E) Immunoblots of undifferentiated ES and 
differentiating EBs at days one, four, seven, ten, and 12 demonstrating down-regulation 
of pluripotency markers (Oct 4,  Nanog) and upregulation of germ layer/lineage markers 
(Tubulin beta-3 (ectoderm), N-cadherin (NCAD) (mesoendoderm), and CD 31 
(endothelial lineage)). Expression levels of known scleroderma autoantigens 
(topoisomerase 1, RNP, and B23) are lowest on differentiation day four and then 
increase, plateauing around day ten.  Actin immunoblot demonstrates equal protein 
loading in each lane.  *Topo 1 and snRNP70 immunoblots performed using scleroderma 




Figure 10:  Patient sera detect novel scleroderma autoantigens in stem cells and 
differentiating progenitor cells.  (A) Immunoblot screen of HeLa cell (H), 
undifferentiated embryonic stem cell (ES), and day ten differentiating embryoid body 
(EB) lysates with randomly selected scleroderma patient sera (SSc-#).  Note that patients 
SSc-1 and SSc-2 have high titer autoantibodies to proteins expressed only in 
undifferentiated ES cells (lanes 8 & 11, black arrows).  Vinculin immunoblot 
demonstrates protein loading in each lane and a representative healthy control serum 
(HC) demonstrates the absence of high titer autoantibodies. (B) Antinuclear antibody 
negative SSc sera contain autoantibodies targeting proteins exclusively expressed in ES 
cells (lane 8, black arrow) and differentiating EBs (lanes 3, 6, 12, black arrows), as well 





Figure 11:  Identification of the autoantigen targeted by SSc-3.  (A) Immunoblot of 
HeLa, ES, and EB lysates as well as additional cell lines (K562 (erythroleukemia), Jurkat 
(T lymphocyte), U2OS (osteosarcoma)) with SSc-3 scleroderma patient serum.  The 50 
kDa protein targeted by SSc-3 autoantibodies is only seen in the EB lysate. Vinculin 
immunoblot (below) shows protein loading in each lane (note: vinculin is not expressed 
by Jurkat cells).  (B) SSc-3 immunoblot of EB lysate after 2D resolution.  First 
dimension: pH 3-10 IEF; second dimension: 10% SDS-PAGE.  (C) SSc-3 immunoblot of 
identically run gel after removal of gel plugs containing the protein of interest.  Insets: 
corresponding colloidal blue stained gels before (B, inset) and after (C, inset) removal of 
gel plugs, prior to transfer to nitrocellulose membranes.  (D) Immunoblot of EB lysates 
fractions showing the SSc-3 targeted protein is insoluble, while vinculin remains in the 







Figure 12:  Confirmation of keratin 8 as a novel scleroderma autoantigen.  (A) 
Immunoblot with rabbit polyclonal anti-keratin 8 antibody of EB lysate after 2D 
resolution.  First dimension: pH 3-10 IEF; second dimension: 10% SDS-PAGE.  (B) The 
nitrocellulose membrane was subsequently stripped of antibody and exposure after 
incubation with a chemiluminescent reagent confirms the absence of previously bound 
anti-rabbit HRP-conjugated secondary antibody.  (C) The membrane was then re-probed 
with scleroderma patient serum SSc-3 and an HRP-conjugated anti-human secondary 
antibody. (D) Precise digital overlay of X-ray film images confirms exact alignment of 
signal from bound polyclonal anti-keratin 8 Ab (red) and scleroderma patient serum SSc-
3 (green).  (E) Immunoblots of mock (-) or pKeratin8 (+) transfected U2OS cells with a 
polyclonal anti-keratin 8 antibody, SSc-3 patient serum, and healthy control serum.  The 
50 kDa keratin 8 protein is only detected in the pKeratin 8 transfected cells by the 
polyclonal anti-keratin 8 antibody and the SSc-3 patient serum, but is not detected in the 




Figure 13:  Identification of HSC70 and fetuin A as novel scleroderma autoantigens.  
(A) Immunoblot with SSc-4 patient serum of EB lysate after 2D resolution.  First 
dimension: pH 3-10 IEF; second dimension: 10% SDS-PAGE.  Note separation of the 
acidic 68 kDa EB antigen (black arrow) and the ubiquitously expressed 70 kDa antigen 
(open arrow).  (B) Identically run 2D gel stained with colloidal blue and with gel plugs 
removed for LC/MS/MS sequencing.  (C) Following transfer to a nitrocellulose 
membrane, immunoblotting with SSc-4 patient serum confirms plucked gel plugs contain 
the antigens of interest.  Areas of emphasis boxed and enlarged directly below. (D) 2D 
immunoblot with monoclonal anti-HSC70 antibody (left), identical gel blotted with SSc-
4 patient serum (middle), and precise digital overlay of X-ray images (right; HSC70 in 
red, SSc-4 in green).  (E-F) Immunoblots comparing protein bands detected with the SSc-
4 patient serum to those detected with a polyclonal anti-fetuin A antibody: (E) Reduced 
(+) and non-reduced (-) EB lysates - note that the 68 kDa antigen (black arrow) is 
detectable exclusively in the reduced lysates; (F) EB lysates before (-) and after (+) 
deglycosylation – note the corresponding reduction in size of the 68 kDa bands with 
deglycosylation (black arrows); (G) HEK293 (human embryonic kidney) cells mock (-) 
and pFetuin A (+) transfected – note detection of the 68 kDa band exclusively in the 
pFetuin A transfected cells by both the commercial anti-fetuin A antibody and the SSc-4 
patient serum.  For SSc-4 blots, HSC70 is indicated by white arrows and the 68 kDa EB 










Figure 14:  Localization of lineage markers and scleroderma autoantigen expression 
in differentiating embryoid bodies.  (A) Indirect immunofluorescence of Oct 4 
expression in day seven EBs, with highest levels of expression along the periphery.  (B)  
mesoendodermal marker NCAD and (C) ectodermal marker Tubulin beta-3 are expressed 
by cells located centrally in day seven EBs.  (D) Colocalization of RNA polymerase III 
expression (red) with Oct 4 (green) demonstrates that RNA polymerase III is upregulated 
in cells expressing Oct 4 in day seven EBs.  (E) Topoisomerase 1 expression is relatively 
uniform in day seven EBs and is not upregulated in Oct 4 expressing cells.  (F & G) Co-
localization of the endothelial cell marker CD31 (green) in day 12 EBs with RNA pol III 
(F, red) and topoisomerase 1 (G, red).  Upregulation of RNA Pol III expression is 
detectable in cells of undetermined lineage (F, white arrows) located near the site of 








Chapter 4:  General Conclusions 
 
The systemic autoimmune diseases are a group of complex, heterogeneous 
diseases united by the presence of immune mediated destruction of target tissues and the 
presence of high titer, disease specific autoantibodies that correlate with clinical 
phenotype and prognosis.  Evidence to date suggests that key insights into mechanisms of 
disease initiation and propagation can be obtained by characterizing the expression and 
modification of these targeted proteins in the cancers and target tissues of patients.  
This investigation sought to further our understanding of these complex diseases 
by (1) the development of an improved approach for the identification of novel 
autoantigens that emphasizes the use of disease relevant antigen sources and a 
multidimensional approach that preserves and takes advantage of potentially relevant 
protein dynamics and (2) applying these methods to test the hypothesis that 
differentiating progenitor cells are targets of the immune response in scleroderma.  This 
work demonstrated that current technologies enable rapid and efficient autoantigen 
discovery, and allow novel autoantigens expressed in pathways relevant to disease 
pathogenesis to be defined.  Moreover, the detection of novel scleroderma autoantigens 
expressed in differentiating stem cells is the first evidence to suggest that a progenitor 
cell involved in tissue repair may be a target of the immune response in this disease.  
Our current model of systemic autoimmunity is that an anti-tumor immune 
response cross-reacts with progenitors involved in tissue repair.  In the setting of tissue 
damage, this cross reactivity results in a cycle of chronic antigen driven immune 
activation that disrupts the tissue repair process.  This model explains features of these 
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diseases that have confounded researchers and clinicians alike, including: (i) The 
association with an increased risk of cancer, the diagnosis of which is temporally related 
to the diagnosis of autoimmunity, and the prognosis of which is better than that of the 
general population; (ii)  The presence of autoantibodies years prior to the onset of 
autoimmune disease in some patients; (iii)  The molecular and clinical heterogeneity of 
these diseases, likely reflecting the heterogeneity of the initiating tumor cells and anti-
tumor lymphocytes; (iv) The self-sustaining and self-amplifying nature of the antigen 
driven immune response; (v) The chronic inflammation and tissue damage that subvert 
the body’s homeostatic regulation and reparative efforts; and (vi) The confounding results 
of experiments identifying autoantigens using traditional cell lines.  This model also 
accounts for the fact that despite the increased risk associated with systemic autoimmune 
diseases, a majority of patients are never diagnosed with cancer.  Successful elimination 
of a nascent tumor and the development of a repertoire of autoreactive lymphocytes that 
go on to cause disease may be the intended and unintended consequences of an effective 
antitumor immune response. 
Autoantibodies found in patient sera are a key link between anti-tumor and anti-
self immune responses.  They are also powerful probes for identifying the antigens 
responsible for driving the immune response, which may lead to the discovery of the 
cellular targets in systemic autoimmunity.  Discovery of these targeted proteins and their 
role in the mechanism of disease offers hope for new clinical measures of disease as well 
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